CA2064815C - Therapeutic heterocyclic compounds - Google Patents
Therapeutic heterocyclic compoundsInfo
- Publication number
- CA2064815C CA2064815C CA002064815A CA2064815A CA2064815C CA 2064815 C CA2064815 C CA 2064815C CA 002064815 A CA002064815 A CA 002064815A CA 2064815 A CA2064815 A CA 2064815A CA 2064815 C CA2064815 C CA 2064815C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- solvate
- salt
- physiologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 140
- 239000000203 mixture Substances 0.000 claims abstract description 129
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 239000012453 solvate Substances 0.000 claims abstract description 37
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000011321 prophylaxis Methods 0.000 claims abstract description 17
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 15
- 206010027599 migraine Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 229940044601 receptor agonist Drugs 0.000 claims description 7
- 239000000018 receptor agonist Substances 0.000 claims description 7
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 6
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 3
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 claims description 3
- 230000002460 anti-migrenic effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000001270 agonistic effect Effects 0.000 claims 2
- 229940125684 antimigraine agent Drugs 0.000 claims 2
- 239000002282 antimigraine agent Substances 0.000 claims 2
- ULSDMUVEXKOYBU-UHFFFAOYSA-N 2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]- Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CC1COC(=O)N1 ULSDMUVEXKOYBU-UHFFFAOYSA-N 0.000 claims 1
- 229940122081 5 Hydroxytryptamine receptor agonist Drugs 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 223
- 239000000047 product Substances 0.000 description 116
- 239000000243 solution Substances 0.000 description 111
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 104
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 88
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 49
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- 239000007787 solid Substances 0.000 description 41
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 34
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 33
- 239000003921 oil Substances 0.000 description 32
- 239000004480 active ingredient Substances 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 27
- 229910017974 NH40H Inorganic materials 0.000 description 26
- 239000000377 silicon dioxide Substances 0.000 description 24
- 238000009472 formulation Methods 0.000 description 23
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000000284 extract Substances 0.000 description 19
- 239000012458 free base Substances 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 239000002798 polar solvent Substances 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 238000000921 elemental analysis Methods 0.000 description 13
- 239000006260 foam Substances 0.000 description 13
- -1 for example Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 239000012279 sodium borohydride Substances 0.000 description 11
- 229910000033 sodium borohydride Inorganic materials 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 239000007868 Raney catalyst Substances 0.000 description 7
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 7
- 229910000564 Raney nickel Inorganic materials 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
- 238000004452 microanalysis Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 235000011150 stannous chloride Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 238000007083 alkoxycarbonylation reaction Methods 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000006396 nitration reaction Methods 0.000 description 4
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 4
- 239000003880 polar aprotic solvent Substances 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 4
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 3
- ANOPNEVQPPHZLO-FVGYRXGTSA-N (4s)-4-[(4-hydrazinylphenyl)methyl]-1,3-oxazolidin-2-one;hydrochloride Chemical compound Cl.C1=CC(NN)=CC=C1C[C@@H]1NC(=O)OC1 ANOPNEVQPPHZLO-FVGYRXGTSA-N 0.000 description 3
- KWSLGOVYXMQPPX-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]-2h-tetrazole Chemical compound FC(F)(F)C1=CC=CC(C2=NNN=N2)=C1 KWSLGOVYXMQPPX-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000007142 ring opening reaction Methods 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- GTVVZTAFGPQSPC-MRVPVSSYSA-N (2r)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-MRVPVSSYSA-N 0.000 description 2
- SVZCLUCFAVAKLH-PFEQFJNWSA-N (4r)-4-[[3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one;hydrate Chemical compound O.C1N(C)CCC(C=2C3=CC(C[C@H]4NC(=O)OC4)=CC=C3NC=2)=C1 SVZCLUCFAVAKLH-PFEQFJNWSA-N 0.000 description 2
- FLRJDZBECNWMSH-PFEQFJNWSA-N (4r)-4-[[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one;hydrobromide Chemical compound Br.C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2C[C@H]1NC(=O)OC1 FLRJDZBECNWMSH-PFEQFJNWSA-N 0.000 description 2
- HAFWELDDNUXLCK-ODZAUARKSA-N (z)-but-2-enedioic acid;hydrate Chemical class O.OC(=O)\C=C/C(O)=O HAFWELDDNUXLCK-ODZAUARKSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 2
- ADZUEEUKBYCSEY-UHFFFAOYSA-N 1h-indole-5-carbaldehyde Chemical compound O=CC1=CC=C2NC=CC2=C1 ADZUEEUKBYCSEY-UHFFFAOYSA-N 0.000 description 2
- YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 description 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000011872 intimate mixture Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- PCLGMKWXPXAGEO-QMMMGPOBSA-N (2s)-2-amino-3-(4-nitrophenyl)propan-1-ol Chemical compound OC[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 PCLGMKWXPXAGEO-QMMMGPOBSA-N 0.000 description 1
- IJJGBUGJQOBNKO-SNVBAGLBSA-N (4r)-4-(1h-indol-5-ylmethyl)-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@@H]1CC1=CC=C(NC=C2)C2=C1 IJJGBUGJQOBNKO-SNVBAGLBSA-N 0.000 description 1
- BSLCGNWSUGHJMV-SBSPUUFOSA-N (4r)-4-[(4-aminophenyl)methyl]-1,3-oxazolidin-2-one;hydrochloride Chemical compound Cl.C1=CC(N)=CC=C1C[C@H]1NC(=O)OC1 BSLCGNWSUGHJMV-SBSPUUFOSA-N 0.000 description 1
- RLXBEGPKQKEJBN-SECBINFHSA-N (4r)-4-[(4-hydrazinylphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(NN)=CC=C1C[C@H]1NC(=O)OC1 RLXBEGPKQKEJBN-SECBINFHSA-N 0.000 description 1
- ANOPNEVQPPHZLO-SBSPUUFOSA-N (4r)-4-[(4-hydrazinylphenyl)methyl]-1,3-oxazolidin-2-one;hydrochloride Chemical compound Cl.C1=CC(NN)=CC=C1C[C@H]1NC(=O)OC1 ANOPNEVQPPHZLO-SBSPUUFOSA-N 0.000 description 1
- CCEJPIYBVGYGEM-MRVPVSSYSA-N (4r)-4-[(4-nitrophenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C[C@H]1NC(=O)OC1 CCEJPIYBVGYGEM-MRVPVSSYSA-N 0.000 description 1
- OFRCMAOTKYANDX-NTISSMGPSA-N (4r)-4-[3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indol-5-yl]-1,3-oxazolidin-2-one;hydrate Chemical compound O.C1N(C)CCC(C=2C3=CC(=CC=C3NC=2)[C@H]2NC(=O)OC2)=C1 OFRCMAOTKYANDX-NTISSMGPSA-N 0.000 description 1
- IJJGBUGJQOBNKO-JTQLQIEISA-N (4s)-4-(1h-indol-5-ylmethyl)-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1CC1=CC=C(NC=C2)C2=C1 IJJGBUGJQOBNKO-JTQLQIEISA-N 0.000 description 1
- BSLCGNWSUGHJMV-FVGYRXGTSA-N (4s)-4-[(4-aminophenyl)methyl]-1,3-oxazolidin-2-one;hydrochloride Chemical compound Cl.C1=CC(N)=CC=C1C[C@@H]1NC(=O)OC1 BSLCGNWSUGHJMV-FVGYRXGTSA-N 0.000 description 1
- ZIRGZEBWUBRYGX-PPHPATTJSA-N (4s)-4-[(4-hydrazinylphenyl)methyl]-3-methyl-1,3-oxazolidin-2-one;hydrochloride Chemical compound Cl.C1OC(=O)N(C)[C@H]1CC1=CC=C(NN)C=C1 ZIRGZEBWUBRYGX-PPHPATTJSA-N 0.000 description 1
- CCEJPIYBVGYGEM-QMMMGPOBSA-N (4s)-4-[(4-nitrophenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C[C@@H]1NC(=O)OC1 CCEJPIYBVGYGEM-QMMMGPOBSA-N 0.000 description 1
- OWLSFSWHAHSZLG-HBUOZDOVSA-N (4s)-4-[[3-[2-(benzylamino)ethyl]-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1OC(=O)N[C@H]1CC1=CC=C(NC=C2CCNCC=3C=CC=CC=3)C2=C1 OWLSFSWHAHSZLG-HBUOZDOVSA-N 0.000 description 1
- JCVYPWLJTZLZKT-ISUPNROZSA-N (4s)-4-[[3-[2-[benzyl(methyl)amino]ethyl]-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one;(z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O.C=1C=CC=CC=1CN(C)CCC(C1=C2)=CNC1=CC=C2C[C@H]1COC(=O)N1 JCVYPWLJTZLZKT-ISUPNROZSA-N 0.000 description 1
- WPPZBQFZQQDGJX-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]-1-methylimidazolidin-2-one Chemical compound OC(=O)\C=C/C(O)=O.C1=C2C(CCN(C)C)=CNC2=CC=C1CC1CNC(=O)N1C WPPZBQFZQQDGJX-BTJKTKAUSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- VOQRWMVOPWWPLW-UHFFFAOYSA-N 1-methylpiperidin-4-one;hydrate Chemical compound O.CN1CCC(=O)CC1 VOQRWMVOPWWPLW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ODZYMSKQIROSOC-UHFFFAOYSA-N 1h-imidazole-4,5-dione Chemical group O=C1NC=NC1=O ODZYMSKQIROSOC-UHFFFAOYSA-N 0.000 description 1
- KHKYWISXKOAOSH-LLVKDONJSA-N 2-[5-[[(4r)-dioxazolidin-4-yl]methyl]-1h-indol-3-yl]ethanamine Chemical compound C1=C2C(CCN)=CNC2=CC=C1C[C@@H]1COON1 KHKYWISXKOAOSH-LLVKDONJSA-N 0.000 description 1
- IFMUGPRJKZZWIJ-NSHDSACASA-N 2-[5-[[(4s)-2-oxo-1,3-oxazolidin-4-yl]methyl]-1h-indol-3-yl]acetonitrile Chemical compound C1OC(=O)N[C@H]1CC1=CC=C(NC=C2CC#N)C2=C1 IFMUGPRJKZZWIJ-NSHDSACASA-N 0.000 description 1
- ODNFQADBSZFWFO-UHFFFAOYSA-N 2-phenylethanethial Chemical compound S=CCC1=CC=CC=C1 ODNFQADBSZFWFO-UHFFFAOYSA-N 0.000 description 1
- VZHPIHOGYVEMFD-UHFFFAOYSA-N 3-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-1h-indole-5-carbaldehyde Chemical compound C1N(C)CCC(C=2C3=CC(C=O)=CC=C3NC=2)=C1 VZHPIHOGYVEMFD-UHFFFAOYSA-N 0.000 description 1
- VNKICNPQYBWHDM-UHFFFAOYSA-N 3-[2-[3-(1-methylpiperidin-4-yl)-1h-indol-5-yl]ethyl]imidazolidine-2,4-dione;hydrochloride Chemical compound Cl.C1CN(C)CCC1C(C1=C2)=CNC1=CC=C2CCN1C(=O)NCC1=O VNKICNPQYBWHDM-UHFFFAOYSA-N 0.000 description 1
- ZGFQKLCCTNCOMJ-UHFFFAOYSA-N 3-[2-[3-(2-aminoethyl)-1h-indol-5-yl]ethyl]imidazolidine-2,4-dione;hydrate;hydrochloride Chemical compound O.Cl.C1=C2C(CCN)=CNC2=CC=C1CCN1C(=O)CNC1=O ZGFQKLCCTNCOMJ-UHFFFAOYSA-N 0.000 description 1
- DBVTYDLZMXNRIN-UHFFFAOYSA-N 3-benzyl-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1CC1=CC=CC=C1 DBVTYDLZMXNRIN-UHFFFAOYSA-N 0.000 description 1
- INUJUEANIWTFOQ-UHFFFAOYSA-N 4,4-diethoxy-N,N-dimethylbutan-1-amine hydrate Chemical compound C(C)OC(CCCN(C)C)OCC.O INUJUEANIWTFOQ-UHFFFAOYSA-N 0.000 description 1
- QKXMWBLNSPNBEY-UHFFFAOYSA-N 4,4-diethoxy-n,n-dimethylbutan-1-amine Chemical compound CCOC(OCC)CCCN(C)C QKXMWBLNSPNBEY-UHFFFAOYSA-N 0.000 description 1
- PDELHPJVSMIQNF-FJOGWHKWSA-N 4-[2-[3-(2-aminoethyl)-1h-indol-5-yl]ethyl]-5-methylimidazolidin-2-one;(z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O.CC1NC(=O)NC1CCC1=CC=C(NC=C2CCN)C2=C1 PDELHPJVSMIQNF-FJOGWHKWSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- LTLKJYMNUSSFAH-UHFFFAOYSA-N 4-chloro-1,1-dimethoxybutane Chemical compound COC(OC)CCCCl LTLKJYMNUSSFAH-UHFFFAOYSA-N 0.000 description 1
- BAQQRABCRRQRSR-UHFFFAOYSA-N 4-hydroxybutylnitrile Chemical compound OCCCC#N BAQQRABCRRQRSR-UHFFFAOYSA-N 0.000 description 1
- CGFGIKNLZTZJDE-UHFFFAOYSA-N 4-oxobutanenitrile Chemical compound O=CCCC#N CGFGIKNLZTZJDE-UHFFFAOYSA-N 0.000 description 1
- WDVRSQXNGVFUSU-UHFFFAOYSA-N 5-(2-nitroethyl)-1h-indole Chemical compound [O-][N+](=O)CCC1=CC=C2NC=CC2=C1 WDVRSQXNGVFUSU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZOEVSPNDPKQDMJ-UHFFFAOYSA-N C(C1=CC=CC=C1)N1CCC(CC1)=O.O Chemical compound C(C1=CC=CC=C1)N1CCC(CC1)=O.O ZOEVSPNDPKQDMJ-UHFFFAOYSA-N 0.000 description 1
- HEJMPMUJKJDUGP-UHFFFAOYSA-N CC(O)=O.CC(O)=O.N1C(=O)N(C)CC1CC1=CC=C(NC=C2CCN)C2=C1 Chemical compound CC(O)=O.CC(O)=O.N1C(=O)N(C)CC1CC1=CC=C(NC=C2CCN)C2=C1 HEJMPMUJKJDUGP-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710171573 Primary amine oxidase Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- MEEMDXOIFOJHDW-UHFFFAOYSA-N acetic acid;5-[(3-piperidin-4-yl-1h-indol-5-yl)methyl]imidazolidine-2,4-dione Chemical compound CC(O)=O.O=C1NC(=O)NC1CC1=CC=C(NC=C2C3CCNCC3)C2=C1 MEEMDXOIFOJHDW-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- GKQTUHKAQKWLIN-UHFFFAOYSA-L barium(2+);dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Ba+2] GKQTUHKAQKWLIN-UHFFFAOYSA-L 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VBXYAKBKJUUJDR-UHFFFAOYSA-N benzaldehyde;hydrate Chemical compound O.O=CC1=CC=CC=C1 VBXYAKBKJUUJDR-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- QKZWXPLBVCKXNQ-ROJLCIKYSA-N dipamp Chemical compound COC1=CC=CC=C1[P@@](C=1C=CC=CC=1)CC[P@@](C=1C(=CC=CC=1)OC)C1=CC=CC=C1 QKZWXPLBVCKXNQ-ROJLCIKYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007904 elastic gelatin capsule Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- QRMKTNANRJCRCY-UHFFFAOYSA-N ethylammonium acetate Chemical compound CC[NH3+].CC([O-])=O QRMKTNANRJCRCY-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- RPMXALUWKZHYOV-UHFFFAOYSA-N nitroethene Chemical compound [O-][N+](=O)C=C RPMXALUWKZHYOV-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3; W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C1-4 alkyl, X is -O-, -S-, -NH-, or -CH2-, Y is oxygen or sulphur and the chiral centre (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions; and Z is a group of formula (iv), (v), or (vi), wherein R1 and R2 are independently selected from hydrogen and C1-4 alkyl and R3 is hydrogen or C1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
Description
Therapeutic Heterocyclic Compounds The present invention is concerned with new chemical compounds, their preparation, pharmaceutical formulations containing them and their use in medicine, particularly the prophylaxis and treatment of migraine.
Receptors which mediate the actions of 5-hydroxytryptamine (5-HT) have been identified in mammals in both the periphery and the brain. According to the classification and nomenclature proposed in a recent article (Bradley et al, Neuropharmac., 25, 563 (1986)), these receptors may be classified into three main types, viz. "5-HT1-like", 5-HT2 and 5-HT3. Various classes of compounds have been proposed as 5-HT agonists or antagonists for therapeutic use, but these have not always been specific to a particular type of 5-HT
receptor. European Patent Specification 0313397 describes a class of 5-HT agonists which are specific to a particular type of "5-HT1-like" receptor and are effective therapeutic agents for the treatment of clinical conditions in which a selective agonist for this type of receptor is indicated. For example, the receptor in question mediates vasoconstriction in the carotid vascular bed and thereby modifies blood flow therein.
The compounds described in the European Specification are therefore beneficial in the treatment or prophylaxis of conditions wherein vasoconstriction in the carotid vascular bed is indicated, for example, migraine, a condition associated with excessive dilation of the carotid vasculature. However, it is within the scope of the earlier application that the target tissue may be any tissue wherein action is mediated by "5-HT1-like"
receptors of the type referred to above.
We have now found a further class of compounds having exceptional "5-HT1-like" receptor agonism and excellent absorption following oral dosing. These properties render the compounds particularly useful for certain medical applications, notably the prophylaxis and .
treatment of migraine, cluster headache and headache associated with vascular disorders, hereinafter referred to collectively as "migraine".
According to the first aspect of the present invention, therefore, there is provided a compound of formula (I) H
cz) ~ (CH ) 2n Z
wherein n is 1, W is a group of formula:
Receptors which mediate the actions of 5-hydroxytryptamine (5-HT) have been identified in mammals in both the periphery and the brain. According to the classification and nomenclature proposed in a recent article (Bradley et al, Neuropharmac., 25, 563 (1986)), these receptors may be classified into three main types, viz. "5-HT1-like", 5-HT2 and 5-HT3. Various classes of compounds have been proposed as 5-HT agonists or antagonists for therapeutic use, but these have not always been specific to a particular type of 5-HT
receptor. European Patent Specification 0313397 describes a class of 5-HT agonists which are specific to a particular type of "5-HT1-like" receptor and are effective therapeutic agents for the treatment of clinical conditions in which a selective agonist for this type of receptor is indicated. For example, the receptor in question mediates vasoconstriction in the carotid vascular bed and thereby modifies blood flow therein.
The compounds described in the European Specification are therefore beneficial in the treatment or prophylaxis of conditions wherein vasoconstriction in the carotid vascular bed is indicated, for example, migraine, a condition associated with excessive dilation of the carotid vasculature. However, it is within the scope of the earlier application that the target tissue may be any tissue wherein action is mediated by "5-HT1-like"
receptors of the type referred to above.
We have now found a further class of compounds having exceptional "5-HT1-like" receptor agonism and excellent absorption following oral dosing. These properties render the compounds particularly useful for certain medical applications, notably the prophylaxis and .
treatment of migraine, cluster headache and headache associated with vascular disorders, hereinafter referred to collectively as "migraine".
According to the first aspect of the present invention, therefore, there is provided a compound of formula (I) H
cz) ~ (CH ) 2n Z
wherein n is 1, W is a group of formula:
Y
NR
X J-wherein R is hydrogen; X is -O-; Y is oxygen; and the chiral centre * in W is in its (S) or (R) form or is a mixture thereof in any proportions; and Z is a group of formula:
wherein R1 and R2 are each methyl; and physiologically acceptable salts and solvates; and physiologically functional derivatives thereof.
Thus the compound of formula (I) having exceptional properties for the treatment and prophylaxis of migraine is N,N-dimethyl-2-[5-(2-oxo-2,3-oxazolidin-4-yl-methyl)-1H-indol-3-yl]ethylamine in either its (S) or (R) form or as a mixture thereof in any proportions. The salts and solvates of this compound, for example, the hydrate maleates, are particularly preferred.
Physiologically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent, i.e., basic compounds. Such salts must clearly have a physiologically acceptable anion. Suitable physiologically acceptable salts of the compounds of the present invention include those derived from acetic, hydrochloric, hydrobromic, phosphoric, malic, malefic, fumaric, citric, sulphuric, lactic or tartaric acid. The succinate and chloride salts are particularly preferred for medical purposes. Salts having a non-physiologically acceptable anion are within the scope of the invention as useful intermediates for the preparation of physiologically acceptable salts and/or for use in non-therapeutic, for example in vitro, situations.
According to a second aspect of the present invention, there is provided a compound of formula (I) or a physiologically acceptable salt, solvate or physiologically functional derivative thereof for use as a therapeutic agent, specifically as a "5-HT1-like"
receptor agonist, for example, as a carotid vasoconstrictor in the prophylaxis and treatment of migraine. As indicated, however, target organs for the present compounds other than the carotid vasculature are within the scope of the present invention.
The amount of a compound of formula (I), or a salt or solvate thereof, which is required to achieve the desired biological effect will depend on a number of factors such as the specific compound, the use for which it is intended, the means of administration, and the recipient.
A typical daily dose for the treatment of migraine may be expected to lie in the range 0.01 to 5mg per kilogram -S-body weight. Unit doses may contain from 1 to 100mg of a compound of formula (I), for example, ampoules for injection may contain from 1 to lOmg and orally administrable unit dose formulations such as tablets or capsules may contain from 1 to 100mg. Such unit doses may be administered one or more times a day, separately or in multiples thereof. An intravenous dose may be expected to lie in the range 0:01 to 0.15mg/kg and would typically be administered as an infusion of from 0.0003 to 0.15mg per kilogram per minute. Infusion solutions suitable for this purpose may contain from 0.01 to lOmg/ml.
when the active compound is a salt or solvate of a compound of formula (I), the dose is based on the cation (for salts) or the unsolvated compound.
Hereinafter references to "compound(s) of formula (I)"
will be understood to include physiologically acceptable salts and solvates thereof.
According to a third aspect .of the present invention, therefore, there are provided pharmaceutical compositions comprising, as active ingredient, at least one compound of formula (I) and/or a pharmacologically acceptable salt or solvate thereof together with at least one pharmaceutical carrier or excipient. These pharmaceutical compositions may be used in the prophylaxis or treatment of clinical conditions for which a "5-HT1-like" receptor agonist is indicated, for example, migraine. The carrier must be pharmaceutically acceptable to the recipient and must be compatible with, i.e., not have a deleterious effect upon the other ingredients in the composition. The carrier may be a solid or liquid and is preferably formulated with at least one compound of formula (I) as a unit dose formulation, for example, a tablet which may contain from 0.05 to 95% by weight of the active ingredient. If desired, other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.
Possible formulations include those suitable for oral, sublingual, buccal, parenteral (for example, subcutaneous, intramuscular, or intravenous), rectal, topical and intranasal administration. The most suitable means of administration for a particular patient will depend on the nature and severity of the condition being treated and on the nature of the active compound, but, where possible, oral administration is preferred.
Formulations suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets or lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions.
Formulations suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically, a flavoured base, such as sugar and acacia or tragacanth and pastilles comprising the _7_ active compound in an inert base, such as gelatin and glycerin or sucrose and acacia.
Formulations suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution is preferably isotonic with the blood of the intended recipient. Although such solutions are preferably administered intravenously, they may also be administered by subcutaneous or intramuscular injection.
Formulations suitable for rectal administration are preferably provided as unit-dose suppositories comprising the active ingredient and one or more solid carriers forming the suppository base, for example, cocoa butter.
Formulations suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils. Suitable carriers for such formulations include petroleum jelly, lanolin, polyethylene glycols, alcohols and combinations thereof.
The active ingredient is typically present in such formulations at a concentration of from 0.1 to 15% w/w.
The formulations of the invention may be prepared by any suitable method, typically by uniformly and intimately admixing the active compounds) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.
_g_ For example, a tablet may be prepared by compressing an intimate mixture comprising a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
Aqueous solutions for parenteral administration are typically prepared by dissolving the active compound in sufficient water to give the desired concentration and then rendering the resulting solution sterile and isotonic.
Thus, according to a fourth aspect of the present invention, there is provided the use of a compound of formula (I) in the preparation of a medicament for the prophylaxis or treatment of a clinical condition for which a "5-HT1-like" receptor agonist is indicated, for example, migraine.
According to a fifth aspect, there is provided a method for the prophylaxis or treatment of a clinical condition in a mammal, for example, a human, for which a "5-HT1-like" receptor agonist is indicated, for example, migraine, which comprises the administration to said mammal of a therapeutically effective amount of a compound of formula (I) or a physiologically acceptable salt, solvate or physiologically functional derivative thereof .
According to a sixth aspect of the invention, compounds of formula (I) may be prepared by reacting a compound of formula (II) (isolated or in situ - infra).
(II) W
~ (CH ) 2n wherein n and W are as hereinbefore defined, with a compound of formula (III) H
L (III) or a carbonyl-protected form thereof, such as the dimethyl or diethyl acetal, wherein L is a suitable leaving group, such as chlorine, or a protected amino group, either of which may be converted in situ to an - 1~ -amino group, or is -NRlRz where Rl and RZ are as hereinbefore defined. The reaction is typically carried out by refluxing the compounds in a polar solvent system, for example, ethanol/water, dilute acetic acid or water in the presence of an acidic ion exchange resin, for example, "Amberlyst 15" (Trade-mark).
Standard N-methylation methods may be used to convert compounds of formula (I) wherein R1 and/or RZ are hydrogen to corresponding compounds (I) wherein R1 and Rz are methyl.
Compounds of formula (I) may be prepared from the corresponding compound wherein R1 - Rz - H by methods of N,N-dimethylation well known to those skilled in the art, for example, by treatment with the appropriate aldehyde in the presence of a reducing system, for example, sodium cyanoborohydride/-acetic acid, in a polar solvent, such as methanol.
Compounds of formula (I) wherein R1 or Rz is methyl and the other is hydroxy may. be prepared from the corresponding compound wherein R1 - R2 - H by N-benzylation using benzaldehyde and a suitable reducing agent, for example, sodium borohydride, in a polar solvent, such as ethanol, followed by N-methylation using a suitable agent, such as the appropriate methyl sulphate, typically in the presence of a base, for example, anhy, potassium carbonate, in a polar aprotic solvent, such as DMF, and finally N-debenzylation, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent, such as ethanol.
Hydrazines of formula (II). may be prepared from the corresponding aniline of formula (IV) NH
(IV) CH
2~n wherein n and W are as hereinbefore defined, by diazotisation followed by reduction. Diazotisation is typically carried out using sodium nitrite/c.HCl and the resulting diazo product reduced in situ using, for example, tin(II) chloride/c.HCl. The resulting hydrazine may be isolated or converted to a compound of formula (I) in situ.
Anilines of formula (IV) may be prepared by reduction of the corresponding p,-nitro compound of formula (V) . ~ N02 (v) CH
2)n wherein n and W are as hereinbefore defined, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent system, such as an acidified mixture of ethanol, water and ethyl acetate.
Anilines of formula (IV) may also be prepared by cyclising a compound of formula (XXXIII) H(R4)N ~ NH2 HX (XXXI I I ) (CH2)n wherein n and X are as hereinbefore defined and R4 is -COZRS where RS is C1_4 alkyl, typically by heating in the presence of a base, such as sodium methoxide.
Compounds of formula (XXXIII) may be prepared by reducing a corresponding C1_4 alkyl ester using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C. The ester, may be prepared by esterifying the corresponding carboxylic acid using, for example, the appropriate alcohol and HC1 or by reducing the corresponding p-nitro compound, for example, by catalytic hydrogenation. Both the acid and the p,-nitro compound may be prepared from the corresponding g-nitroaminoacid, the acid by N-alkoxycarbonylation using, for example, RSOCOCl where RS is as hereinbefore def fined, followed by reduction of the nitro group, for example, by catalytic hydrogenation, or by reduction of the nitro group followed by N-alkoxycarbonylation, and the g-nitro compound by N-alkoxycarbonylation (as for the acid) followed by esterification using, for example, the appropriate alcohol and HC1, or by esterification followed by N-alkoxycarbonylation. The g-nitroaminoacid may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature, for example, by p,-nitration of the corresponding aminoacid using, for example, c.H2S02/c.HN03 at 0°C .
p-Nitro compounds of formula (V) may be prepared by reacting a compound of formula (VI) H(R)N . ~ N~2 HX (vI ) (CH ) 2n wherein n, R and X are as hereinbefore defined, with a compound of formula (VII) / L (VII) Y =C~
L' wherein Y is as hereinbefore def fined and L and L' , which may be the same or different, are suitable leaving groups, for example, chlorine, ethoxy, trichloromethyl, trichloromethoxy, or imidazoyl, for example, in the case where L - L' - chlorine, in a non-polar solvent, such as toluene, in the presence of a base, for example, potassium hydroxide.
- IS -Compounds of formula (VI) may be prepared by ring-opening a compound of formula (V), for example, by refluxing in 2N aqu. KOH.
Compounds of formula (VI) may be prepared by esterification of the corresponding carboxylic acid, typically by treatment with thionyl chloride and an appropriate alcohol at -10°C. followed by reduction of the ester using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C. The acid may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature, for example, by p-nitration of the corresponding aminoacid using, for example, c.H2S04/c.HN03 at 0°C .
Compounds of formula (III) and (VII) may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature.
p-Nitro compounds of formula (V) may also be prepared by g-nitration of a compound of formula (XXXVI) (XXXVI ) CH ~ .
2~n wherein n and W are as hereinbefore defined using, for example, c.H2S02/c.HN03 at 0°C.
Compounds of formula (XXXVI) may be prepared by reacting a compound of formula (XXXVII) H(R)N
HX (XXXVII) (CH ) 2n wherein n, R and X are as hereinbefore defined, with a compound of formula (VII) wherein Y, L and L' are as hereinbefore defined, typically in the presence of a base, for example, potassium hydroxide in a non-polar solvent, such as toluene.
Compounds of formula (XXXVII) may be prepared by reducing the corresponding nitro compounds, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent, such as ethanol. The nitro compound corresponding to the compound of formula (XXXVII) may be prepared by reacting a compound of formula (XXIV) (XXIV) 2 n+1 wherein n is as hereinbefore defined, with paraformaldehyde in a polar aprotic solvent, such as DMF, in the presence of a base, for example, sodium methoxide, at 0°C, or by esterification of the corresponding carboxylic acid, 'typically by treatment with thionyl chloride and an appropriate alcohol at -10°C., followed by reduction of the ester group using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C.
The compound of formula (XXIV), the acid and the aldehyde may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature.
Compounds of formula (I) may also be prepared by reacting a compound of formula (XV) wherein n, R, X and Z are as hereinbefore defined, with a compound of formula (VII) wherein Y, L and L' are as hereinbefore defined, for example, in the case where L = L' = ethoxy, by heating in the presence of a base, for example, potassium carbonate.
Compounds of formula (XV) may be prepared by ring-opening a compound of formula (I) wherein n, Z and W are as hereinbefore defined in which R, X and Y are as hereinbefore defined, for example, by refluxing in 2N
aqu. KOH.
Compounds of formula (XV) may be prepared by esterification of the corresponding carboxylic acid, typically by treatment with thionyl chloride and an appropriate alcohol at -10°C., followed by reduction of the ester using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C. The acid may be prepared by ring-opening a compound of formula (XVI) H
NR ~ N
XVI
( >
R N
(CH2)n .
Z
O
wherein n, R and Z are as hereinbefore defined and R6 is hydrogen or benzyl, typically by refluxing in water in the presence of a base, for example, barium hydroxide.
Compounds of formula (XVI ) wherein n = 1 may be prepared by reducing a compound of formula (XVII) H
R
O N / CH ~ (XVI I ) (CH
R6 2)n_1 Z
N
O
wherein n, R, R6 and Z are as hereinbefore defined, typically by catalytic hydrogenating using, for example, Pd/C in a polar solvent system, such as ethanol/water.
Alternatively, an enantioselective reducing agent, such as Rh(cod)(dipamp) -BF2 (JCS. Chem. Comm. 275 (1991)), may be used to reduce the double bond and thereby introduce a chiral centre at the 4-position of the dioxoimidazole ring.
Compounds of formula (XVII) may be prepared by reacting a compound of formula (XVIII) H
(xvIII) OHC ~
{CH2)n-1 Z
wherein n and Z are as hereinbefore defined, with, in the case where R6 is to be hydrogen, a compound of formula (X) wherein R is as hereinbefore defined, typically by heating in glac. acetic acid in the presence of ammonium acetate.
Compounds of formula (XVIII) may -be prepared by the reduction hydrolysis of the corresponding nitrile, typically using Raney nickel and sodium hypophosphite in a mixture of water, acetic acid and pyridine.
Compounds of formula (XVI) wherein R6 is benzyl may be prepared by reacting a compound of formula (XXXV) NR ~ NHNH2 (xxxv) Bz ~ (CH2)~
O
wherein n and R are as hereinbefore defined, with a compound of formula (III) wherein L is as hereinbefore defined, typically using the reaction conditions described above for the reaction of (II) with (III).
Hydrazines of formula (XXXV) may be prepared from the corresponding aniline, typically using the reaction conditions described above for the conversion of (IV) to (II). The aniline may be prepared by reducing the corresponding g-nitro compound, typically using the reaction conditions described above for the conversion of (V) to (IV). The g-nitro compound may be prepared by reacting the corresponding p-nitroaminoacid with benzyl isocyanate in the presence of base, for example, potassium hydroxide, in a polar solvent, such as water.
The p-nitroaminoacid may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature, for example, by ~-nitration of the corresponding aminoacid using, for example, c . H2S04/c . HN03 at 0°C .
Compounds of formula (XV) may be prepared by reducing a compound of formula (XX) H
02N ~ N .
(xx) HX
(CH2)n Z
wherein n, X and Z are as hereinbefore defined, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent, such as ethanol.
Compounds of formula (XX) may be prepared by reacting a compound of (XXI ) H
N
02N w (CH2)n+1 Z (xxI) wherein n and Z are as hereinbefore defined, with paraformaldehyde in a polar aprotic solvent, such as DMF, in the presence of a base, fo,r example, sodium methoxide, at 0°C .
Compounds of formula (XXI) may be prepared by reacting a compound of formula (XXII) H
(xxll) ~2N ~ CH
2~n+1 wherein n is as hereinbefore defined, with, the appropriate compound of formula (XXVIII) wherein R3 is as hereinbefore defined, typically by heating in glac.
acetic acid.
Compounds of formula (XXII) wherein n = 1 may be prepared by reducing a compound of formula (XXIII) H
N (XXIII) ~2N~CH iCH~
(CH2)n-1 wherein n is as hereinbefore defined, using, for example, sodium borohydride and 40% w/v aqu. NaOH in a polar aprotic solvent such as acetonitrile, at 0°C.
Compounds of formula (XXIII) may be prepared by heating the appropriate aldehyde with nitromethane in the presence of ammonium acetate. The aldehyde may be prepared from a compound of formula (XIX) wherein n is as hereinbefore defined using the reaction conditions described above for preparing a compound of formula (XVIII) from the corresponding nitrile.
Compounds of formula (XXII) where n - 1 may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature.
Compounds of formula (XXI) wherein n - 1 may also be prepared from a compound of formula (XXXIX) H
. ~ N
(XXXIX) ~2N ~ CH ~ CH ~ CH
2~n-1 Z
wherein n and Z are as hereinbefore defined, using reaction conditions analogous to those used to convert (XXIII) to (XXII). Compounds of formula (XXXIX) may be prepared from a compound of formula (XVIII) wherein n and Z are as hereinbefore defined using reaction conditions analogous to those used to prepare (XXIII) from the appropriate aldehyde and nitromethane.
Compounds of formula (I) may also be prepared from a compound of formula (XXXI) H
N
W ' / (xxxl ) (CH2)n wherein n and W are as hereinbefore defined, by methods known to those skilled in the art or obtainable from the chemical literature, for example, by treatment with (COL)2, where L is a suitable leaving group, for example, chlorine, to give the corresponding 3-COCOL compound which may then be treated with HNR1R2, where R1 and Rz are as hereinbefore defined, and reduced using, for example, lithium aluminium hydride. Alternatively, the compound of formula~(XXXI) may be treated with CH20/KCN to give the corresponding 3-cyanomethyl compound which may then be catalytically hydrogenated over Raney nickel in the presence of NHR1R2 as hereinbefore defined.
The aforementioned 3-cyanomethyl compound may also be prepared by cyclising a compound of formula (XXXX) I NHN = CH(CH2)2CN
i W \ ~CH2~n ~ cxxr~p wherein n and W are as hereinbefore defined, typically by refluxing in an aprotic solvent, such as chloroform, in the presence of polyphosphate ester.
Compounds of formula (XXXX) may be prepared by reacting a compound of formula (II) wherein n and W are as hereinbefore defined with 3-cyanopropanal, or a carbonyl-protected form thereof, such as (the diethyl acetal, typically in an aqueous acid, for example, dil. HC1.
Compounds of formula (XXXI) may be prepared by reducing a compound of formula (XXXII) H
(XXXII) W
~ (CH2)n SPh wherein n and W are as hereinbefore defined, typically by heating with Raney nickel in a polar solvent, such as IPA.
Compounds of formula (XXXII) may be prepared by reacting a hydrazine of formula (II) wherein n and W are as hereinbefore defined with phenylthioacetaldehyde, or a carbonyl-protected form thereof, for example, the diethyl acetal, in a polar solvent, such as acidified ethanol.
For a better understanding of the invention, the following Examples are given by way of illustration.
SYNTHETIC AND REFERENCE EXAMPLES
Synthetic Example 1 Preparation of (S)-2-f5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine (a) (S)-Methyl 4-nitrophenvlalanate hydrochloride Methanol (110m1) was treated dropwise with thionyl chloride (26.3g) at -10°C and L-4-nitrophenylalanine (Fluka, 21.7g) added to the resulting solution as a solid. The mixture was stirred overnight at room temperature and the methanol removed in vacuo to give the desired product as a pale yellow solid (21.2g) .
(b) (S)-2-Amino-3-(4-nitrophenyl)propanol The product from step (a) (21.2g) was dissolved in ethanol/water (190m1, 100/90 v/v) and the solution added dropwise at 0°C to a stirred solution of sodium borohydride (l3.Og) in ethanol/water (190m1, 100/90 v/v). The resulting mixture was refluxed for 2.5 hours, cooled and the precipitate filtered off.
The ethanol was partially removed from the filtrate in vacuo and the resulting precipitate filtered off and dried to give the desired product as a pale yellow solid (7.5g).
(c) (S)-4-(4-Nitrobenzyl)-1,3-oxazolidin-2-one The product from step (b) (4.9g) was suspended in toluene, the suspension, cooled to 0°C and a solution of potassium hydroxide (7.Og) in water (56m1) added dropwise. A solution of phosgene (62.5m1 of a 12%
w/v solution in toluene) was added dropwise to the resulting solution over 30 minutes and stirring continued for 1 hour. The mixture was extracted with ethyl acetate and the extracts washed with brine, dried and evaporated in vacuo to give a yellow oil. Crystallisation from ethyl acetate gave the desired product as pale yellow crystals (2 . 3g) .
(d) (S)-4-(4-Aminobenzyl)-1,3-oxazolidin-2-one hydro-chloride A suspension of the product from step (c) (0.79g) and 10% palladium on carbon (0.26g) in a mixture of ethanol (15m1), water (llml), ethyl acetate (2.Om1) and aqu. 2N HC1 (2.3m1) was stirred under 1 atmos.
pressure of hydrogen until uptake ceased. The mixture was filtered through Hyflo (Trade-mark) and the filtrate evaporated in vacuo to give the desired product as a pale yellow foam (0.79g).
(e) (S)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride The product from step (d) (0.79g) was suspended in water (4.8m1) and c.HCl (8.lml) added dropwise. The resulting mixture was cooled to -5°C and a solution of sodium nitrite (0.24g) in water (2.4m1) added dropwise to the stirred mixture. over 15 minutes followed by 30 minutes stirring at -5 to 0°C. The solution was then added at 0°C over 15 minutes to a stirred solution of tin (II) chloride (3.Sg) in c.HCl (6.9m1), followed by 3 hours stirring at room temperature. The solution was evaporated in vacuo and the residue triturated with ether to give the desired product as a pale yellow solid (0.96g).
(f) (S)-2-f5-(2-Oxo-1 3-oxazolidin-4-ylmethyl)-1H-indol-3_yllethylamine The product from step (e) (0.84g) was dissolved in ethanol/water (125m1, 5:1) and the solution treated with 4-chlorobutanaol dimethylacetal (JACS 1365 (1951), 0.52g). The mixture was refluxed for 2 hours, the solvent removed in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant. The desired product was obtained as a colourless oil (0.21g).
Salt of Synthetic Example 1 Maleate Ethanolic malefic acid (1.0 equiv.) was added dropwise to the free base (0.21g) and the ethanol evaporated in vacuo. The resulting gum was freeze-dried from water to give the desired product as a white lyopholate (0.22g), [a] 21D -5. 92° (c = 0.3, MeOH) .
1H NMR (DMSO-d6, b) : 2.7-3.5 (6H, m, CH2) , 3.35 (2H, s, NHz) , 4.05 (2H, m, CHZ) , 4.25 (1H, m, CH) , 6.05 (2H, s, malefic acid) , 6.98 (1H, d, Ar) , 7.2 (1H, s, Ar) , 7.3 (1H, d, Ar), 7.4 (1H, s, Ar), 7.75 (1H, s, NH) and 10.9 (1H, s , NH ) .
Microanalysis: C 55.03 (54.96), H 5.54 (5.85), N 10.30 (10.68) .
Synthetic Example 2 Preparation of (S)-N N-dimethYl-2-f5-(2-oxo-1,3-oxazoli-din-4-ylmethyl)-1H-indol-3-yllethylamine 0.9 isoprot~anol-ate 0.5 hydrate A solution of formaldehyde (0.03g) in methanol (1.8m1) was added to a solution of the free base from step (f) of Synthetic Example 1 (0.12g) and sodium cyanoborohydride (0.04g) in a mixture of methanol (5.5m1) and glac. acetic acid (0.14g) and the resulting mixture stirred overnight at room temperature. The pH was adjusted to 8.0 using aqu. KZC03 and the mixture extracted with ethyl acetate.
The combined extracts were washed with brine, dried and evaporated to give a colourless oil (0.14g) which crystallised from isopropanol to give the desired product as a white crystalline solid (O.lOg), mp 139-141°C.
1H NMR (DMSO-ds, 8) : 2.2 (6H, s, NMe2~, 2.5 (2H, m, CHZAr) , 2 .7-3 . 0 (4H, m, CHz) , 4.1 (2H, m, CH2) , 4.3 (1H, m, CH) , 6.9 (1H, d, Ar), 7.1 (1H, s, Ar), 7.3 (1H, d, Ar), 7.4 (1H, s, Ar) , 7.7 (1H, s, NHCO) and 10.7 (1H, s, NH) .
Microanalysis: C 64.26 (64.11), H 8.28 (8.34), N 12.02 (12.00) [a] 22D - 5 . 79° (c = 0 . 5, MeOH) Salts of Synthetic Example 2 Maleate A solution of malefic acid (0.17g) in ethanol (5m1) was added to a solution of the free base (0.5g) in ethanol (5m1). The mixture was evaporated in vacuo and the resulting oil triturated with ether and methanol to give the maleate salt as a white solid which was recrystallised from ethanol (0.45g), mp 151-152°C.
Hydrochloride Ethereal HC1 (1.1 equivs.). was added dropwise to a stirred solution of the free base (0.35g) in methanol (lml) at 0°C. The hydrochloride salt precipitated as an oil. The mixture was evaporated in vacuo and the resulting foam crystallised from isQpropanol to give the desired product as a white solid (0.36g), mp 118-120°C, [a] 23D -9 . 35 (c = 0 . 31, water) .
Succinate A solution of succinic acid (0.36g) in ethanol (lOml) was added to a solution of the free base (l.Og) in ethanol (lOml). The mixture was evaporated in vacuo and the resulting foam triturated with isopropanol to give the succinate salt as a white solid (l.Og), mp 122-123°C.
Benzoate A solution of benzoic acid (0.37g) in ethanol (lOml) was added to a solution of the free base (l.Og) in ethanol (lOml). The mixture was evaporated in vacuo and the resulting foam crystallised from ethyl acetate to give the benzoate salt as a white solid (0.74g), mp 90-92°C.
Synthetic Example 3 Alternative preparation of (S)-N N-dimethyl-2-f5-(2-oxo-1 3-oxazolidin~lmethyl)-1H-indol-3-yllethylamine 0.9 iso-propanolate 0.5 hydrate 4-Dimethylaminobutanal diethylacetal (Croatica Chemica Acta 36, 103 (1964), 3.9g) was added to a solution of the product from step (e) of Synthetic Example 1 (10.4g) in a mixture of acetic acid (50m1) and water (150m1) and the resulting mixture refluxed for 4.5 hours. The mixture was cooled, evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H (50:8:1) as eluant to give the desired product as a pale yellow oil which crystallised from isopropanol as a white crystalline solid (3.5g), mp 138-140°C. 1H NMR, microanalysis and [a]D as for product of Synthetic Example 2.
Reference Example 4 Preparation of (~)-3-(1-methyl-4-piperidyl)-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indole (a) 3-(1-Methyl-1 2,3,6-tetrahydro-4-pyridyl)-1H-indole-5-carbonitrile 5-Cyanoindol (Aldrich, 20.Og) was added to a solution of KOH (22.4g) in methanol (200m1). N-Methyl-4-piperidone (Aldrich, 40.4g) was then added dropwise and the resulting mixture refluxed for 4 hours, then cooled and poured into water. The resulting precipitate was filtered off and dried to give the desired product as a pale pink crystalline solid (32.6g) .
(b) 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-1H-indole-5-carbaldehyde Raney nickel (ca lOg) was added to a solution of the product from step (a) (5.Og) and sodium hypophos-phite (6.Og) in a mixture of water (25m1), glac.
acetic acid (25m1) and pyridine (50m1) at 45°C.
The resultin mixture was stireed at 45°C for 1 hour, cooled and basified to pH 9 with 0.88 NH40H. The mixture was filtered through Hyflo and the filtrate extracted with chloroform. The combined extracts were dried and evaporated in vacuo to give the desired product as an off-white solid which was recrystallised from ethanol (2.4g).
(c) 5-f3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-1H
indol-5-ylmethylenel-2,4-imidazolidinedione A mixture of the product from step (b) (2.4g), hydantoin (Aldrich, 0.98g) and ammonium acetate (0.74g) in glac. acetic acid (2.4m1) was heated at 120°C for 4 hours. The mixture was cooled and the resulting precipitate filtered off and dried to give the desired product as,a yellow solid (2.4g).
(d) (~) -5- (2 , 5-Dioxo-4-imidazolidinylmethyl) -3- (1-methyl-4-piperidyl)-1H-indole The product from step (c) (2.4g) was suspended in a mixture of water (100m1) and ethanol (200m1) and 10% w/w Pd/C (0.25g) added. The mixture was stirred under 1 atmos. pressure of hydrogen for 17 hours when uptake was complete. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo to give the desired product as a colourless solid (2.4g) .
(e) (~) -3- f3- (1-Methyl-4-piperidyl) -1H-indol-5-yll -alanine A solution of the product from step (d) (2.4g) and barium hydroxide hydrate (8.4g) in water (50m1) was refluxed for 72 hours, then cooled and evaporated in vacuo. The residue was taken up in hot methanol and filtered to remove barium salts. The filtrate was evaporated in vacuo, the residue dissolved in water and dry ice added to precipitate barium carbonate. The latter was filtered off and the filtrate evaporated in vacuo to give the desired product as a yellow foam (1.3g).
(f) (~)-Methyl 3-f3-(1-methyl-4-piperidyl)-1H-indol-5-yllalanate A solution of the product from step (e) (6.2g) in methanol (40m1) was added dropwise to a solution of thionyl chloride (2.9m1) in methanol (35m1) at -10°C. The resulting mixture was stirred overnight at room temperature, then evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H (30:8:1) as eluant. The eluate was evaporated in vacuo to give the desired product as a yellow foam (4.8g) .
(g) (+) -3- [3- (1-Methyl-4-piperidyl) -1H-indol-5-vll -2-amino-1-propanol A solution of the product from step (f) (4.8g) in water (20m1) and ethanol (20m1) was added dropwise to a suspension of sodium borohydride (0.61g) in a mixture of water ( 2 Oml ) and ethanol ( 2 Oml ) at 0°C .
The resulting mixture was refluxed for 3 hours, then evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant. The eluate was evaporated in vacuo to give the desired product as a colourless foam ( 1 . 6g) .
(h) (+) -3- (1-Methyl-4-giperid~l) -5- (2-oxo-1, 3-oxazo-lidin-4-ylmethyl)-1H-indole A mixture of the product from step (g) (1.6g), diethyl carbonate (0.73m1) and potassium carbonate (0.08g) was heated at 130°C for 5 hours. The mixture was cooled, taken up in methanol and the insoluble potassium carbonate filtered off. The filtrate evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant. The eluate was evaporated in vacuo and the residue recrystallised from isopro-panol/ether to give the desired product as a colour-less crystalline solid (l.lg), mp 191-192°C.
1H NMR (DMSO-d6, b) : 1.6-1.8 (2H; 2 x CHNMe) , 2 .8-2 .1 (4H, 2 x CHZ) , 22.2 (3H, s, NMe) , 2.6-3.0 (2H, 2 x CHNMe: 1H, CH: 2H, CHZAr), 3.9-4.1 (2H, m, CH20), 4.2-4.4 (1H, m, CHN), 6.9 (1H, d, Ar), 7.1 (1H, d, Ar), 7.3 (1H, d, Ar), 7.4 (1H, s, Ar), 7.8 (1H, s, NHCO) and 10.7 (1H, S, NH).
Salt of Reference Example 4 Hydrochloride c.HCl (1.0 equiv.) was added dropwise to a stirred solution of the free base (l.lg) in ethanol (5m1) at 5°C.
The addition of ether to the resulting mixture precipitated the desired product as a white solid (l.lg), mp 235-236°C (dec) .
Reference Example 5 Alternative preparation of (+)-3-(1-methyl-4-piperidvl)-5-(1 3-oxazolidin-4-ylmethyl)-1H-indole (a) 1H-Indole-5-carbaldehyde Raney nickel (6.7g) was added to a solution of 5-cyanoindole (Aldrich, lO.Og) and sodium hypophos-phite (20.0 g) in a mixture of water (73m1), glac.
acetic acid (73m1) and pyridine (145m1) at 45°C for 2 hours, then cooled and filtered through Hyflo. The filtrate was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, 10% aqu. citric acid. 1N aqu. HC1, water and brine, dried and evaporated in vacuo to give the desired product as a buff solid which was recrystallised from chloroform (7.5g).
(b) 5- (2-nitroethen~l) -1H-indole A mixture of the product from step (a) (7.5g), ammonium acetate (1.5g) and nitromethane (77m1) was heated at 110°C for 2 hours, then cooled and evaporated in vacuo. The residue was triturated with water to give the desired product as a yellow solid which was filtered off and dried (9.2g).
(c) 5-(2-Nitroethyl)-1H-indole A solution of sodium borohydride (2.Og) and 40%
w/v aqu. NaOH was added dropwise to a solution of the product from step (b) (1.9g) in acetonitrile (55m1) at 0°C. The pH was maintained at 3-6 by periodic additions of 2N aqu._ HC1. The resulting solution was stirred at 0°C for 2 hours, then diluted with water and extracted with DCM. The combined extracts were washed with brine, dried and evaporated in vacuo to give a yellow oil which was eluted through a silica column using chloroform as eluant to give the desired product as a pale yellow oil (0.78g).
(d) 3~1-Methyl-1, 2 , 3 , 6-tetrahydro-4-wridyl) -5- (2-nitroethyl)-1H-indole N-Methyl-4-piperidone (Aldrich, 4.2g) was added to a solution of the product from step (c) (2.3g) in glac. acetic acid (35m1) at 100°C for 1 hour, cooled and poured into a mixture of 0.88 NH40H
(6lml) and ice (61g). The resulting solid was filtered off, dried and recrystallised from ethanol to give the desired product as a white solid (1.6g) .
(e) (~)-3-f3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-1H-indol-5-yll-2-amino-1-propanol Sodium methoxide (0.30g) was added to a solution of the product from step (d) (1.5g) in DMF (l5ml) at 0°C. To the resulting solution was added dropwise a suspension of paraformaldehyde (0.19g) 9n DMF
(20m1). The resulting mixture was stirred at 0°C
for 1.5 hours, then poured into water and extracted with ethyl acetate. The combined extracts were washed with water and brine, dried and evaporated in vacuo to give a yellow oil which was eluted through a silica column using DCM/EtOH/NH40H
(50:8:1) as eluant to give the desired product as an off-white solid (0.85g which was recyrstallised from ethanol.
(f) (~)-3-f3-(1-Methyl-4-piperidyl)-1H-indol-5-yll-2-amino-1-pro~anol The product from step (e) (0.08g) was dissolved in ethanol (25m1) and 10% w/w Pd/C (0.23g) added. The mixture was stirred under 1 atmos. pressure of hydrogen for 7 hours when uptake was complete. The mixture was filtered through celite and the filtrate evaporated in vacuo to give the desired product as colourless oil which was eluted through a silica column using DCM/EtOH/NH40H (50:8:1) as eluant.
(g) (~)-3-(1-Methyl-4-piperidyl)-5-(1,3-oxazolidin-4-ylmethyl)-1H-indole A mixture of the product from step (f) (1.6g), diethyl carbonate (0.71g) and potassium carbonate (0.08g) was heated at 130°C for 5 hours. The mixture was cooled, taken up in-methanol and the insoluble potassium carbonate filtered off. The filtrate was evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant to give a colourless foam which was crystallised from isopropanol/ether to give the desired product as a colourless crystalline solid (l.lg), mp 191-192°C. 1H NMR and microanalysis as for product of Reference Example 4.
Synthetic Example 6 Preparation of (R)-2-[5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine (a) (R)-4-(4-nitrobenzyl)-1,3-oxazolidin-2-one A solution of D-4-nitrophenylalanine (Fluka, 53g) in dimethoxyethane (250m1) was warmed to 67°C and BF3.Et20 (Aldrich, 37m1) added over 1 hour. The resulting solution was stirred at 67°C for 1 hour, then heated to 80°C and BH3,Me2S (Aldrich, 40m1) added over 1 hour at 80-85°C. The resulting solution was heated at 85°C for 4 hours, then cooled and methanol (40m1) added. The solution was heated to 85°C and the solvents removed by distillation to 1/3 of the original bulk. 6N aqu. NaOH (136m1) was added to the hot solution which was then heated at 85°C for hour, cooled and DCM (100m1) added. The solution was cooled to -15 to -20°C and a solution of tri-chloromethyl chloroformate (Aldrich, 18.2m1) in DCM
(23m1) added at below -10°C. The pH was maintained at 9-11 by periodic additions of 6N aqu. NaOH. The resulting solution was stirred at room temperature for 1 hour, then diluted with water and extracted with DCM. The combined extracts were washed with water and brine, dried and evaporated in vacuo to give the desired product as a pale brown solid which was recrystallised from ethyl acetate to give a pale yellow solid (35g) , mp 113-115°, [a] 21D +46 .47°
(c = 0.56, MeOH).
(b) (R)-4-(4-Aminobenzyl)-1,3-oxazolidin-2-one hydro-chloride The product from step (a) (lO.Og) was suspended in a mixture of water (120m1), ethanol (60m1) and 2N aqu.
HC1 (22.5m1) and 10% w/w Pd/C (l.Og) added. The mixture was stirred under 1 atmos. pressure of hydrogen for 8 hours when uptake was complete. The mixture was filtered through Hyflo (Trade-mark for a finely divided filtration material) and the filtrate evaporated in vacuo to give the desired product as a colourless glass (10.3g).
(c) (R)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hvdrochloride The product from step (b) (10.3g) was suspended in water (53m1) and c.HCl (106m1) added dropwise. The resulting mixture was cooled to -5°C and a solution of sodium nitrite (3.2g) in water (30m1) added drop-wise to the stirred mixture over 15 minutes followed by 30 minutes stirring at -5 to-OC°. The solution was then added at 0°C over 15 minutes to a stirred solution of tin (II) chloride (51g) in c.HCl (9lml), followed by 3 hours stirring at room temperature.
The solution was evaporated in vacuo and the residue triturated with ether to give the desired product as a pale yellow solid (llg).
(d) (R)-2-(5-(2-Oxa-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl)-ethylamine The product from step (c) (8.8g) was dissolved in ethanol/water (500m1, 5:1 v/v) and the solution treated with 4-chlorobutanal dimethylacetal (J.
Amer. Chem. Soc. 1365 (1951), 5.5g). The mixture was refluxed for 2 hours, the solvent removed in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H (30:8:1 v/v/v) as eluant. The desired product was obtained as a pale yellow oil (0.6og) .
Salt of Synthetic Example 6 Hydrochloride c.HCl (0.06m1) was added dropwise to a stirred solution of the free base (0.16g) in ethanol (2m1) at 0°C. The hydrochloride salt was precipitated.as a fawn solid, mp 269-271°C, [a] Z1D t5. 88° (c = 0 .27, MeOH) .
Synthetic Example 7 Preparation of (R)-N N-dimethyl-2-f5-(2-oxo-1,3-oxazoli-din-4-ylmethyl)-1H-indol-3-yllethylamine A solution of 35% w/v aqu. formaldehyde (0.3m1) in methanol (2.Om1) was added to a solution of the product from step (d) of Synthetic Example 6 (0.44g) and sodium cyanoborohydride (0.13g) in a mixture of methanol (8.5m1) and glac. acetic acid (0.51g) at 10°C and the resulting mixture stirred at room temperature for 2.5 hours. 2N
aqu. NaOH (l.3ml) was added, then sodium borohydride (0.19 g) followed by 2N aqu. HCl (1.3 ml) . The methanol was evaporated in vacuo and the remaining solution diluted with water, taken to pH 7 with solid potassium carbonate and washed with ethyl acetate. Further potassium carbonate was added to Ph 11 and the solution extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give the desired product as a white foam (0.45g) .
Salt of Synthetic Example 7 Hydrochloride c.HCl (0.16m1) was added dropwise to a stirred solution of the free base (0.45g) in ethanol (4.5m1 at 0°C. The mixture was evaporated in vacuo and the resulting foam triturated with ethyl acetate to give the desired product as a white solid, mp 130°C, [a] Z1D +5 . 15° (c = 0 . 77, MeOH) .
Reference Example 8 Preparation of (S)-N,N-dimethyl-2-f5-(2-thia-1,3-oxazo-lidin-4-~lmethyl)-1H-indol-3-~rllethylamine hydrochloride (a) (S)-N N-Dimethyl-2-[5-(2-amino-1-propanol)-1H-indol-3-yllethy-lamine A solution of the hydrochloride salt of the product of Synthetic Example 2 (0.33g) in 2N aqu. KOH (lOml) was refluxed for 4 hours, then cooled and extracted with ethyl acetate. The combined extracts were dried and evaporated in vacuo to give the desired product as a colourless oil (0.25g).
(b) ~S)-N N-Dimethyl-2-f5-(2-thia-1,3-oxazolidin-4-yl methyl)-1H-indol-3-yllethylamine hydrochloride A solution of N,N'-thiocarbonylimidazole (Aldrich, 0.21g) in THF (4m1) was added dropwise to a stirred solution of the product from step (a) (0.31g) in THF (4ml) and the mixture refluxed for 23 hours, then cooled and evaporated in vacuo. The residue was chromatographed through a silica column using DCM/EtOH/NH40H (20:8:1) as eluant to give the desired product as a colourless oil.
Salt of Reference Example 8 Hvdrochloride 1M Ethanolic HC1 (1.0 equiv.) was added dropwise to the free base and the ethanol evaporated in vacuo. The resulting gum was freeze-dried from water to give the desired product as a white solid (0.17g), mp 133-136°C, (softens 183°C) , [a] 24.sD -29.8 (c = 0 . 5 , water) .
Reference Example 9 Preparation of (S)-2-f5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yllethylamine hydrobromide (a) ~S)-3-Methyl-4-(4-nitrobenzyl)-2-oxazolidinone Sodium hydride (0.808 as a 60% w/w dispersion in oil) was added at room temperature to a stirred solution of the product from step (c) of Synthetic Example 1 (4.4g) in dry THF (150m1). The mixture was stirred for 1.5 hours, then dimethyl sulphate (2.1m1) was added and stirring continued for a further 16 hours. More sodium hydride (0.40g) was added and stirring continued for another 2 hours.
The mixture was evaporated in vacuo and the residue suspended in ethyl acetate and filtered. The filtrate was evaporated in vacuo and the residue crystallised from ethyl acetate/hexane to give the ' desired product as yellow crystals (3.7g), mp 146-147°C, [a] 23D +64 .5° (c = 1 . 0, MeOH) .
(b) (S)-3-Methyl-4-(4-aminobenzyl)-2.-oxazolidinone hydrochloride A suspension of the product from step (a) (4.Og) and 10% w/w Pd/C (0.20g) in a mixture of ethanol (70m1) and dil. HCl (2N aqu. HC1 (12m1) + water (55m1)) was hydrogenated at 45 psi for 1 hour.
The mixture was filtered through Hyflo and the filtrate evaporated in vacuo to give the desired product as a foam.
(c) (S)-3-Methyl-4-(4-hydrazinobenzyl)-2-oxazolidinone hydrochloride A solution of the product from step (b) (4.1g) in water (24m1) was cooled to -5°C and c.HCl (40m1) added. A solution of sodium nitrate (1.2g) in water (12m1) was then added and stirring continued for 0.5 hour. The resulting solution was added dropwise at -5°C to a stirred solution of stannous chloride dehydrate (18.8g) in c.HCl (34m1). The resulting mixture was stirred at 0°C for 2.5 hours, then evaporated in vacuo. The residue was taken up in water, brought to pH 2.5 using lON aqu. NaOH and filtered. The filtrate was evaporated in vacuo and the residue triturated with ethanol and filtered.
The filtrate was evaporated in vacuo to give the desired product as a froth.
(d) (S)-2-[5-(3-Methyl-2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol-3-yl]ethylamine hydrobromide 4-Chlorobutanal dimethylacetal (J. Amer. Chem. Soc.
1365 (1951) 2.3g) was added to a stirred solution of the product from step (c) (4.4g) in ethanol/-- water (150m1/20m1) and the mixture refluxed for 2 hours. The cooled mixture was evaporated in vacuo, and the residue eluted through a silica column using DCM/MeOH/NH40H (60:8:1) as eluant to give a brown oil (1.7g). A portion of this (0.25g) was taken up in ethanol and treated with an excess of HBr in acetic acid (ca 45% w/v). The resulting solution was evaporated in vacuo and the residue triturated with ether, then crystallised from ethanol/hexane to give the desired product as pale yellow crystals (0.14g), mp 203-205°C, [a] z5D +29. 9° (c = 0. 5, MeOH) .
Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 10 Preparation of (S)-N,N-dimethyl-2-[5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yllethylamine maleate 0.75 hydrate Sodium cyanoborohydride (0.14g) followed by glac. acetic acid (0.54m1) were added at room temperature to a stirred solution of the free base (0.52g) from step (d) of Reference Example 9 in methanol (9.Om1). When effervescence was complete, a solution of 37% w/v aqu.
formaldehyde (0.16g) in methanol (2.Om1) was added and the mixture stirred for 1 hour, then diluted with water, saturated with potassium carbonate and extracted with ethyl acetate. The combined extracts were evaporated in vacuo and the residue eluted through a silica column using DCM/MeOH/NH40H (60:8:1) as eluant to give the free base of the desired product as a colourless oil (0.25g).
The latter was dissolved in ethanol (lOml), treated with a solution of malefic acid (0.09g) in ethanol (lml) and the resulting solution evaporated in vacuo to give an oil which was triturated with ether, the freeze-dried from water to give the desired product as a colourless glass, [a] ZZD +24 . 5° (c - 0 . 5, MeOH) . Elemental analysis, 1H NMR
and MS were consistent with the proposed structure.
Synthetic Example 11 Preparation of (S)-N-benzyl-2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl)ethylamine maleate 0.75 hydrate Benzaldehyde (0.70g) was added at room temperature to a stirred solution of the compound of. Synthetic Example 1 (1.7g) in ethanol (20m1). The solution was stirred for 36 hours, then sodium borohydride (0.25g) was added in portions and stirring continued for a further 2 hours.
The solution was evaporated in vacuo and the residue cooled, acidified with 2N aqu. HC1, basified with sodium bicarbonate, saturated with potassium carbonate and extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give an oil which was eluted through a silica column using DCM/EtOH/NH40H (100:8:1) as eluant to give the free base of the desired product as a yellow froth (1.6g). A portion of this (0.13g) was dissolved in ethanol (lOml), treated with a solution of malefic acid (43mg) in ethanol (lml) and the resulting solution evaporated in vacuo. The residue was freeze-dried from water to give the desired product as a pale yellow powder (0.16g) [a]24D +1.4° (c - 0.5, MeOH).
Elemental analysis, 1H NMR and MS were consistent with the proposed structure.
Synthetic Example 12 Preparation of (S)-N-benzyl-N-methyl-2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl)ethylamine maleate hydrate Anhy. potassium carbonate (0.34g), was added at room temperature to a solution of the free base of Synthetic Example 11 (0.45g) in DMF (8.Om1). The suspension was stirred for 0.5 hour, then a solution of dimethyl sulphate (0.17g) in DMF (2.Om1) was added and stirring continued for a further 3 hours. Water (40m1) was added and the mixture extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give a yellow oil which was eluted through a silica column using DCM/EtOH/NH40H (100:8:1) as eluant to give the free base of the desired product as a colourless oil (0.32g). A
portion of this (73mg) was dissolved in ethanol (lOml), treated with a solution of malefic acid (23mg) in ethanol (lml) and the resulting solution evaporated in vacuo.
The residue was freeze-dried from water to give the desired product as a pale yellow powder, [a]24D +3.1° (c -0.5, MeOH). Elemental analysis, 1H NMR and MS were consistent with the proposed structure.
Synthetic Example 13 Preparation of (S)-N-methyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yllethylamine maleate 0.5 hydrate A suspension of the free base of the product of Synthetic Example 12 (0.25g) and 10% w/w Pd/C (O.lOg) in ethanol (25m1) was hydrogenated for 16 hours. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was eluted through a silica column using DCM/EtOH/NH40H (30:8:1) as eluant to give the free base of the desired product (0.14g). The latter was dissolved in ethanol (lOml), treated with a solution of malefic acid (0.06g) in ethanol (lml) and the resulting solution evaporated in vacuo. The residue was freeze-dried from water to give the desired product as a hygroscopic solid, [a] 25D -5 .4° (c - 0 . 5, MeOH) .
Elemental analysis and 1H NMR were consistent with proposed structure.
Reference Example 14 Preparation of (S)-3-(1-methyl-1,2,3,6-tetrahydro-4-gyridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole 0.33 methanolate 0.75 hydrate (a) (S)-3-Phenylthio-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indole Phenylthioacetaldehyde diethylacetal (JCS. Chem.
Comm. 924 (1978), 9.1g) was added at room temperature to a stirred solution of the product from step (e) of Synthetic Example 1 (9.8g) in a mixture of ethanol (150m1) and water (100m1).
c.HCl (5 drops) was added and the mixture stirred at room temperature for 2 days, then partially evaporated in vacuo. The resulting aqueous sus-pension was extracted with ethyl acetate,and the combined extracts washed with water and evaporated in vacuo to give a brown oil. The latter was eluted through a silica column using DCM/EtOH/NH40H
(150:8:1) as eluant to give the desired product as a pale yellow oil (5.Og).
(b) (S)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole Raney nickel (3.Og) was added to a solution of the product from step (a) (3.1g) in IPA (150m1) and the suspension refluxed for 1 hour. More Raney nickel (2.Og) was added and refluxing continued for a further 2 hours. The suspension was filtered hot through Hyflo and the filtrate evaporated in vacuo to give an oil. the latter was eluted through a silica column using ethyl acetate as eluant to give the desired product as a froth (1.3g). 1H NMR and MS
were consistent with the proposed structure.
(c) (S)-3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1 3-oxazolidin-4-ylmethyl)-1H-indole 0.33 methanolate 0.75 hydrate 1-Methyl-4-piperidone (0.478, Aldrich) was added to a stirred solution of the product from step (b) (0.30g) in glac. acetic acid (2.Om1) and the mixture stirred at 100°C for 2 hours. The cooled mixture was poured onto ice/NH40H (20m1) and the resulting solid filtered off. The latter was eluted through a silica column using DCM/EtOH/NH40H
(60:8:1) as eluant and crystallised from ethyl acetate to give the desired product as a colour-less solid (O.llg) , mp 225-227°C, [a,] 2°D -45.4° (c =
0.5. 1N aqu. HC1). Elemental analysis and 1H NMR
were consistent with the proposed structure.
Reference Example 15 Preparation of (S)-3-(1-methyl-4 ~iperidyl)-5-oxo-1,3-oxazolidin-4-ylmeth~rl)-1H-indole hydrobromide A suspension of the product of Reference Example 14 (0.35g) and 10% w/w Pd/C (O.lOg) in a mixture of methanol (lOml), water (lOml) and 1N aqu. Hcl was hydrogenated for 5 hours. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was basified with NH40H, evaporated in vacuo and eluted through a silica column using DCM/EtOH/NH40H (45:8:1) as eluant to give an oil. The latter was taken up in ethanol (5.Oml) and treated with an excess of HBr in acetic acid (ca 45%
w/v) to give the desired product as colourless crystals (0 .20g) , mp 260-261°C [a] Z1D -5.2° (c - 0.5, water) .
Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 16 Preparation of (R)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol hydrate (a) (R)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride By steps identical to steps (a) to (c) of Synthetic Example 6, D-4-nitrophenylalanine was converted to -Sg-(R)-4-(4-hydrazinobenzyl)-2-oxazolidinone hydro-chloride.
(b) (R)-3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1,3-oxazolidin-4-yl)-1H-indole hydrate By steps analogous to steps (a) to (c) of Reference Example 14, the product from step (a) was converted to (R)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole hydrate, mp 229-231°C, [a]1aD +24.9° (c = 0.5. 1N aqu. HCl).
Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 17 Preparation of (R)-3-(1-methyl-4-piperidyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole hydrobromide.
By a method analogous to that of Reference Example 15, the product of Synthetic Example 16 was converted to (R)-3-(1-methyl-4-piperidyl)-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indole hydrobromide, mp 260-261°C, [a]19D +4.6°
(c - 0.5, water). Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 18 Preparation of (R)-3-(1-benzyl-1 2 3 6-tetrahydro-4-wridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole hydrate 1-Benzyl-4-piperidone (Aldrich, 2.8g) was added to a stirred suspension of (R)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole (l.Og), the immediate precursor of the product of Reference Example 16, in glac. acetic acid (20m1) and stirred at 100°C for 3 hours. The cooled mixture was evaporated in vacuo and the residue taken up in methanol, basified with NH40H and evaporated in vacuo to give a dark tar. The latter was eluted through a silica column using DCM/EtOH/NH40H (100:8:1) as eluant and treated with DCM. The resulting precipitate was filtered off to give the desired product as yellow crystals (0.25g), mp 169-170.5°C. Elemental analysis and 1H NMR
were consistent with the proposed structure.
Reference Example 19 Preparation of (R) -3- (4-piperidyl) -5- (2-oxo-1 3-oxazo-lidin-4-ylmethyl)-1H-indol hydrobromide A suspension of the product from Reference Example 18 (0.25g) and 10% w/w Pd/C (O.TOg) in methanol (25m1) was hydrogenated at 90 psi for 20 hours when uptake ceased.
The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was eluted through a silica column using DCM/EtOH/NH40H (30:8:1) as eluant to give an oil. The latter was taken up in IPA and treated with an excess of HBr in acetic acid (ca 45% w/v) to give a hygroscopic solid which was freeze-dried from water to give the desired product as a pale brown powder.
Elemental analysis and 1H NMR were consistent. with the proposed structure.
Reference Example 20 Preparation (~)-N,N-dimethyl-2-f5-(1-thio-2-thia-3-oxazo-lidin-4-ylmethyl)-1H-indol-3-yl]ethylamine acetate Carbon disulphide (90,1) was added to a stirred solution of the product from step (a) of Reference Example 8 (0.31g) and potassium hydroxide (0.08g) in ethanol (3.8m1) and the mixture refluxed, then evaporated in vacuo. The residue was extracted with ether, acidified and chromatographed using a silica reverse phase HPLC
column and eluting with 10-a90% v/v water/acetonitrile with O.1M aqu. ammonium acetate buffer at pH 4.0 over 20 minutes to give the desired product (O.Olg) and, after treatment with HCl, the product of Reference Example 8 (O.llg) . Both were freeze-dried from water and gave 1H
NMR and MS which were consistent with the proposed structures.
Synthetic Example 21 Preparation of (~)-N,N-dimethyl-2-f5-(2-oxo-2 3-oxazo-lidin-5-vlmethyl)-1H-indol-3-yllethylamine hydrochloride (a) (~)-1-Nitromethyl-2=phenylethanol Sodium methoxide (l.lg) was added to a stirred solution of nitromethane (Aldrich, 12.2g) in methanol (100m1) at 0°C and the mixture stirred for minutes. A solution of phenylacetaldehyde (Aldrich, 24.Og) in methanol (50m1) was added drop-wise over 15 minutes and the mixture stirred for 45 minutes at 0°C, then brought to room temperature over 1 hour and stirred overnight. The mixture was evaporated in vacuo and the residue taken up in water and extracted with ether. The combined extracts were washed with water and brine and evaporated in vacuo to give the desired product as a yellow oil (29.Og).
(b) (~)-1-Aminomethyl-2-phenvlethanol hydrochloride A suspension of the product from step (a) (lO.Og) and 10% w/w Pd/C (l.Og) in ethanol (250m1) was hydrogenated until uptake ceased. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was taken up in ethyl acetate and extracted with 2N aqu. HC1. The combined extracts were washed with ethyl acetate, then evaporated in vacuo to give the desired product as a pinkish white solid (6.8g).
(c) (~)-5-Benzyl-1,3-oxazolidin-2-one A solution of KOH (9.4g) in water (85m1) was added to a stirred solution of the product from step (b) (5.1g) in toluene (150m1) at 0°C. A solution of phosgene (9.8g) in toluene (78.4m1 - 12.5% w/v) was added dropwise over 15 minutes and the mixture brought to room temperature, then stirred overnight.
The aqueous phase was separated and extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give the desired product as a white solid (2.2g), mp 106-108°C. Elemental analysis was consistent with the proposed structure.
(d) (~) -5- (4-Nitrobenzyl) -1, 3-oxazolidin-2-one c.H2S04 (1.6m1) was added to the product from step (c) at 0°C followed by c.HN03 (0.33m1, ca 0.05m1/5 minutes) also at 0°C. The mixture was stirred for 0.5 hour at 0°C and then for 0.5 hour at room temperature. Water/ice (100m1) was added and the mixture extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give a yellow oil which was recrystallised from ethyl acetate to give the desired product as a white powder (0.4g), mp 143-146°C.
(e) (~)-5-(4-Aminobenzyl)-1,3-oxazolidin-2-one hydro-chloride A suspension of the product from step (d) (1.4g) and 10% w/w Pd/C (0.14g) in a mixture of water (21m1), ethanol (28m1) and 2N aqu. HCl (3.2m1) was hydro-genated for 2 hours when uptake ceased. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo to give the desired product as a pale yellow foam (1.4g).
(f) (~)-N,N-Dimethvl-2-f5-..(.2-oxo-1,3-oxazolidin-5-ylmethyl)-1H-indol-3-yllethylamine hydrochloride c.HCl (14.5m1) was added to a stirred solution of the product from step (e) (1.4g) in water (8.5m1) at 0°C. A solution of sodium nitrite (0.43g) in water (4.3m1) was added dropwise over 15 minutes at 0°C and the mixture stirred for 0.5 hour at 0°C.
The mixture was then added dropwise to a stirred solution of tin (II) chloride (6.8g) in c.HCl (12.4m1) at 0°C over 15 minutes. The mixture was brought to room temperature over 1 hour, then evaporated in vacuo. The residue was taken up in water (30m1), brought to pH 2.5 using lON aqu. NaOH
and the precipitated salts filtered off. 4-Di-methylaminobutanal diethylacetal (Croatica Chemica Acta 36, 103 (1964), l.lg) followed by 'Amberlyst 15' ion exchange resin (Aldrich, 3.Og) was added to the filtrate and the mixture heated for 3 hours at 100°C, filtered and the filtrate evaporated in vacuo.
The residue was treated with hot ethanol, filtered and the filtrate evaporated in vacuo. The residue was triturated with ethyl acetate, filtered and the filtrate evaporated in vacuo. The residue was recrystallised from ethanol to give the desired product as a pale yellow solid (0.75g), mp 280-281°C.
1H NMR and MS were consistent with the proposed structure.
Synthetic Example 22 Preparation of (S)-N,N-dimethyl-2-f5-(2-oxo-1 3-oxazoli-din-4-ylmethyl)-1H-indol-3-yllethylamine (a) (S)-5-(4-Nitrobenzyl-1,3-imidazolidin-2 4-dione Benzyl isocyante (Aldrich, 3.2g) was added to a solution of L-4-nitrophenylalanine (Aldrich, 4.2g) and potassium hydroxide (1.3g) in water (40m1) at 0°C. The mixture was heated at 60-70°C for 2 hours, filtered and the filtrate acidified with c.HCl to give an off-white solid which was filtered off, suspended in 2N aqu. HCl (20m1) and refluxed for 2 hours. The cooled mixture was diluted with water and filtered to give the desired product as a white solid (5.6g) .
(b) (S)-N,N-Dimethyl-2-f5-(2-oxo-1 3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine By steps identical to steps (d) to (f) of Synthetic Example 1 and Synthetic Example 2 or steps (d) and (e) of Synthetic Example 1 and Synthetic Example 3 and steps (e) to (h) of Reference Example 4, the product from step (a) was converted to (S)-N,N-di-methyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine.
Synthetic Example 23 Preparation of (S)-N,N-dimethyl-2-f5-(2-oxo-1 3-oxazo-lidin-4-ylmethyl)-1H-indol-3-yllethylamine (a) (S)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride By steps analogous to steps (a) to (c) of Synthetic Example 6, L-4-nitrophenylalanine was converted to (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride.
(b) (S) -4- (4- f2- (3-cvanopropvlidene) hvdrazinol benzvl 1,3-oxazolidin-2-one 1M aqu. HCl (4.Om1) was added to a solution of the product from step (a) (2.4g) in water (35m1) . 3-Cyanopropanol diethylacetal (Aldrich, 1.7g) was added at room temperature and the mixture stirred for 2 hours. Further acetal (0.20g) was added and the mixture stirred for another 20 minutes. The aqueous phase was decanted from the resulting gum and extracted with ethyl acetate. The extracts were combined with the gum and evaporated in vacuo to give the desired product (2.5g).
(c) (S)-3-Cyanomethyl-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol A solution of the product from step (b) (2.5g) and polyphosphate ester (20.Og) in chloroform (40m1) was refluxed for 20 minutes. Ice was added to the cooled mixture and the chloroform evaporated in vacuo. The remaining aqueous phase was extracted with ethyl acetate and the combined extracts evaporated in vacuo to give the desired product as a pale yellow oil (1.8g).
(d) (S)-N,N-Dimethvl-2-f5-(2-oxo-1 3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine A suspension of the product from step (c) (1.3g) and 10% w/w Pd/C (l.Og) in 30% w/w ethanolic dimethyl-amine (25m1) was hydrogenated for 24 hours and filtered through Hyflo. Fresh Pd/C (0.7g) and ethanolic dimethylamine (5ml) were added to the filtrate and hydrogenation continued for a further 16 hours. The mixture was filtered through a silica column using DCM/EtOH/NH40H (40:8:1) as eluant to give the desired product as a colourless foam (0.3g). Elemental analysis and 1H NMR were con-sistent with the proposed structure.
Reference Examples 24 to 31 By methods analogous to those described in Synthetic and Reference Examples 1 to 23, the following compounds were prepared. The NMR and microanalysis for each compound were consistent with the proposed structure.
24) 2-[5-(3-Methyl-2-oxoimidazolidin=4-ylmethyl)-1H-indol-3-yl]-ethylamine maleate 0.75 hydrate, mp 94-98°C;
25) 2-[5-(3-Methyl-2-oxoimidazolidin-4-ylmethyl)-1H-indol-3-yl]-N,N-dimethylethylamine maleate 0.95 hydrate (white lyopholate);
26) 2-(5-[2-(2,5-Dioxoimidazolidinyl)ethyl]-1H-indol-3-yl)ethylamine hydrochloride hydrate, mp 83-85°C;
27) 2-(5-[2-(2,5-Diozoimidazolidinyl)ethyl]-1H-indol-3-yl)-N,N-dimethylethylamine maleate hydrate (pale yellow lyopholate);
28) 5-[2-(2,5-Dioxoimidazolidinyl)ethyl]-3-(1-methyl-4-piperidinyl)-1H-indole hydrochloride, mp 320-322°C
(dec) ;
29) 2-[5-(5-Methyl-2-oxoimidazolidin-4-ylethyl)-1H-indol-3-yl]ethylamine maleate hydrate, mp 99°C
(softens 88°C) ;
30) 5-[3-(4-Piperidyl)-1H-indol-5-ylmethyl]-2,4-imidazolidinedione acetate 1.4 hydrate, mp 92-93°C;
(sofens 86°C) and 31) 2-[5-(1-Methyl-2-oxo-4-imidazolidinylmethyl)-1H-indol-3-yl]ethylamine diacetate 2.75 hydrate (pale yellow lyopholate).
PHARMACEUTICAL FORMULATION EXAMPLES
In the following Examples, the "active ingredient" may be any compound of formula (I) and/or a physiologically acceptable salt, solvate or physiologically functional derivative thereof.
(1) Tablet formulations ( i ) Oral Mg/tablet A B C
Active ingredient 25 25 25 Avicel (Trade-mark) 13 - 7 Lactose 78 47 -Starch (maize) - 9 -Starch (pregelatinised, NF15) - - 32 Sodium starch glycollate 5 - -Povidone 3 3 -Magnesium stearate 1 1 1 (ii) Sublingual Ma/tablet D E
Active ingredient 25 25 Avicel 10 -Lactose - 36 Mannitol 51 57 Sucrose 3 Acacia - 3 Povidone 3 -Magnesium stearate 1 1 Formulations A to E may be prepared by wet granulation of the first six ingredients with the povidone, followed by addition of the magnesium stearate and compression.
(iii) Buccal Ma/tablet Active ingredient 25 Hydroxypropylmethyl cellulose (HPMC) 25 Polycarbophil 39 Magnesium stearate 1 The formulation may be prepared by direct compression of the admixed ingredients.
(2) Capsule formulations ( i ) Powder Ma/capsule F G
Active ingredient 25 25 Avicel (Trade-mark for a micro-crystalline cellulose) 45 -Lactose 153 -Starch (1500 NF) - 117 Sodium starch glycollate -Magnesium stearate 2 2 Formulations F and G may be prepared by admixing the ingredients and filling two-part hard gelatin capsules with the resulting mixture.
(ii) Liquid fill Mg/capsule H I
Active ingredient 25 25 Macrogol 4000 BP (Trade designation for a polyethylene glycol) 200 -Lecithin - 100 Arachis oil - 100 Formulation H may be prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling two-part hard gelatin capsules therewith.
Formulation I may be prepared by dispersing the active ingredient in the lecithin and arachis oil and filling soft, elastic gelatin capsules with the dispersion.
(iii) Controlled release M~psule Active ingredient 25 Avicel (Trade-mark for a micro-crystalline cellulose) 123 Lactose 62 Triethylcitrate 3 Ethyl cellulose 12 The formulation may be prepared by mixing and extruding the first four ingredients and spheronising and drying the extrudate. The dried pellets are coated with ethyl cellulose as a release controlling membrane and filled into two-part, hard gelatin capsules.
(3) Intravenous injection formulation by weight Active ingredient 2%
Hydrochloric acid ) q.s. to pH 7 Citrate buffer ) Water for Injections to 100%
The active ingredient is taken up on the citrate buffer and sufficient hydrochloric acid added to affect solution and adjust the pH to -. The resulting solution is made up to volume and filtered through a micropore filter into sterile glass vials which are sealed and oversealed.
(4) Intranasal formulation by weight Active ingredient 0.5%
Hydrochloric acid ) q.s. to pH 7 Citrate buffer ) Methyl hydroxybenzoate 0.2%
Propyl hydroxybenzoate 0.02%
Water for Injections to 100%
The active ingredient is taken up in a mixture of the hydroxybenzoates and citrate buffer and sufficient hydrochloric acid added to affect solution and adjust the pH to 7. The resulting solution is made up to volume and filtered through a micropore filter into sterile glass vials which are sealed and oversealed.
(5) Intramuscular injection formulation Active ingredient 0.05 g Benzyl alcohol 0.10 g Glycofurol 75 (Trade-mark) 1.45 g Water for Injections q.s. to 3.00 ml The active ingredient is dissolved in the glycofurol.
The benzyl alcohol is added and dissolved and water added to 3 ml. The mixture is filtered through a micropore filter into sterile glass vials which are sealed and oversealed.
NR
X J-wherein R is hydrogen; X is -O-; Y is oxygen; and the chiral centre * in W is in its (S) or (R) form or is a mixture thereof in any proportions; and Z is a group of formula:
wherein R1 and R2 are each methyl; and physiologically acceptable salts and solvates; and physiologically functional derivatives thereof.
Thus the compound of formula (I) having exceptional properties for the treatment and prophylaxis of migraine is N,N-dimethyl-2-[5-(2-oxo-2,3-oxazolidin-4-yl-methyl)-1H-indol-3-yl]ethylamine in either its (S) or (R) form or as a mixture thereof in any proportions. The salts and solvates of this compound, for example, the hydrate maleates, are particularly preferred.
Physiologically acceptable salts are particularly suitable for medical applications because of their greater aqueous solubility relative to the parent, i.e., basic compounds. Such salts must clearly have a physiologically acceptable anion. Suitable physiologically acceptable salts of the compounds of the present invention include those derived from acetic, hydrochloric, hydrobromic, phosphoric, malic, malefic, fumaric, citric, sulphuric, lactic or tartaric acid. The succinate and chloride salts are particularly preferred for medical purposes. Salts having a non-physiologically acceptable anion are within the scope of the invention as useful intermediates for the preparation of physiologically acceptable salts and/or for use in non-therapeutic, for example in vitro, situations.
According to a second aspect of the present invention, there is provided a compound of formula (I) or a physiologically acceptable salt, solvate or physiologically functional derivative thereof for use as a therapeutic agent, specifically as a "5-HT1-like"
receptor agonist, for example, as a carotid vasoconstrictor in the prophylaxis and treatment of migraine. As indicated, however, target organs for the present compounds other than the carotid vasculature are within the scope of the present invention.
The amount of a compound of formula (I), or a salt or solvate thereof, which is required to achieve the desired biological effect will depend on a number of factors such as the specific compound, the use for which it is intended, the means of administration, and the recipient.
A typical daily dose for the treatment of migraine may be expected to lie in the range 0.01 to 5mg per kilogram -S-body weight. Unit doses may contain from 1 to 100mg of a compound of formula (I), for example, ampoules for injection may contain from 1 to lOmg and orally administrable unit dose formulations such as tablets or capsules may contain from 1 to 100mg. Such unit doses may be administered one or more times a day, separately or in multiples thereof. An intravenous dose may be expected to lie in the range 0:01 to 0.15mg/kg and would typically be administered as an infusion of from 0.0003 to 0.15mg per kilogram per minute. Infusion solutions suitable for this purpose may contain from 0.01 to lOmg/ml.
when the active compound is a salt or solvate of a compound of formula (I), the dose is based on the cation (for salts) or the unsolvated compound.
Hereinafter references to "compound(s) of formula (I)"
will be understood to include physiologically acceptable salts and solvates thereof.
According to a third aspect .of the present invention, therefore, there are provided pharmaceutical compositions comprising, as active ingredient, at least one compound of formula (I) and/or a pharmacologically acceptable salt or solvate thereof together with at least one pharmaceutical carrier or excipient. These pharmaceutical compositions may be used in the prophylaxis or treatment of clinical conditions for which a "5-HT1-like" receptor agonist is indicated, for example, migraine. The carrier must be pharmaceutically acceptable to the recipient and must be compatible with, i.e., not have a deleterious effect upon the other ingredients in the composition. The carrier may be a solid or liquid and is preferably formulated with at least one compound of formula (I) as a unit dose formulation, for example, a tablet which may contain from 0.05 to 95% by weight of the active ingredient. If desired, other physiologically active ingredients may also be incorporated in the pharmaceutical compositions of the invention.
Possible formulations include those suitable for oral, sublingual, buccal, parenteral (for example, subcutaneous, intramuscular, or intravenous), rectal, topical and intranasal administration. The most suitable means of administration for a particular patient will depend on the nature and severity of the condition being treated and on the nature of the active compound, but, where possible, oral administration is preferred.
Formulations suitable for oral administration may be provided as discrete units, such as tablets, capsules, cachets or lozenges, each containing a predetermined amount of the active compound; as powders or granules; as solutions or suspensions in aqueous or non-aqueous liquids; or as oil-in-water or water-in-oil emulsions.
Formulations suitable for sublingual or buccal administration include lozenges comprising the active compound and, typically, a flavoured base, such as sugar and acacia or tragacanth and pastilles comprising the _7_ active compound in an inert base, such as gelatin and glycerin or sucrose and acacia.
Formulations suitable for parenteral administration typically comprise sterile aqueous solutions containing a predetermined concentration of the active compound; the solution is preferably isotonic with the blood of the intended recipient. Although such solutions are preferably administered intravenously, they may also be administered by subcutaneous or intramuscular injection.
Formulations suitable for rectal administration are preferably provided as unit-dose suppositories comprising the active ingredient and one or more solid carriers forming the suppository base, for example, cocoa butter.
Formulations suitable for topical or intranasal application include ointments, creams, lotions, pastes, gels, sprays, aerosols and oils. Suitable carriers for such formulations include petroleum jelly, lanolin, polyethylene glycols, alcohols and combinations thereof.
The active ingredient is typically present in such formulations at a concentration of from 0.1 to 15% w/w.
The formulations of the invention may be prepared by any suitable method, typically by uniformly and intimately admixing the active compounds) with liquids or finely divided solid carriers, or both, in the required proportions and then, if necessary, shaping the resulting mixture into the desired shape.
_g_ For example, a tablet may be prepared by compressing an intimate mixture comprising a powder or granules of the active ingredient and one or more optional ingredients, such as a binder, lubricant, inert diluent, or surface active dispersing agent, or by moulding an intimate mixture of powdered active ingredient and inert liquid diluent.
Aqueous solutions for parenteral administration are typically prepared by dissolving the active compound in sufficient water to give the desired concentration and then rendering the resulting solution sterile and isotonic.
Thus, according to a fourth aspect of the present invention, there is provided the use of a compound of formula (I) in the preparation of a medicament for the prophylaxis or treatment of a clinical condition for which a "5-HT1-like" receptor agonist is indicated, for example, migraine.
According to a fifth aspect, there is provided a method for the prophylaxis or treatment of a clinical condition in a mammal, for example, a human, for which a "5-HT1-like" receptor agonist is indicated, for example, migraine, which comprises the administration to said mammal of a therapeutically effective amount of a compound of formula (I) or a physiologically acceptable salt, solvate or physiologically functional derivative thereof .
According to a sixth aspect of the invention, compounds of formula (I) may be prepared by reacting a compound of formula (II) (isolated or in situ - infra).
(II) W
~ (CH ) 2n wherein n and W are as hereinbefore defined, with a compound of formula (III) H
L (III) or a carbonyl-protected form thereof, such as the dimethyl or diethyl acetal, wherein L is a suitable leaving group, such as chlorine, or a protected amino group, either of which may be converted in situ to an - 1~ -amino group, or is -NRlRz where Rl and RZ are as hereinbefore defined. The reaction is typically carried out by refluxing the compounds in a polar solvent system, for example, ethanol/water, dilute acetic acid or water in the presence of an acidic ion exchange resin, for example, "Amberlyst 15" (Trade-mark).
Standard N-methylation methods may be used to convert compounds of formula (I) wherein R1 and/or RZ are hydrogen to corresponding compounds (I) wherein R1 and Rz are methyl.
Compounds of formula (I) may be prepared from the corresponding compound wherein R1 - Rz - H by methods of N,N-dimethylation well known to those skilled in the art, for example, by treatment with the appropriate aldehyde in the presence of a reducing system, for example, sodium cyanoborohydride/-acetic acid, in a polar solvent, such as methanol.
Compounds of formula (I) wherein R1 or Rz is methyl and the other is hydroxy may. be prepared from the corresponding compound wherein R1 - R2 - H by N-benzylation using benzaldehyde and a suitable reducing agent, for example, sodium borohydride, in a polar solvent, such as ethanol, followed by N-methylation using a suitable agent, such as the appropriate methyl sulphate, typically in the presence of a base, for example, anhy, potassium carbonate, in a polar aprotic solvent, such as DMF, and finally N-debenzylation, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent, such as ethanol.
Hydrazines of formula (II). may be prepared from the corresponding aniline of formula (IV) NH
(IV) CH
2~n wherein n and W are as hereinbefore defined, by diazotisation followed by reduction. Diazotisation is typically carried out using sodium nitrite/c.HCl and the resulting diazo product reduced in situ using, for example, tin(II) chloride/c.HCl. The resulting hydrazine may be isolated or converted to a compound of formula (I) in situ.
Anilines of formula (IV) may be prepared by reduction of the corresponding p,-nitro compound of formula (V) . ~ N02 (v) CH
2)n wherein n and W are as hereinbefore defined, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent system, such as an acidified mixture of ethanol, water and ethyl acetate.
Anilines of formula (IV) may also be prepared by cyclising a compound of formula (XXXIII) H(R4)N ~ NH2 HX (XXXI I I ) (CH2)n wherein n and X are as hereinbefore defined and R4 is -COZRS where RS is C1_4 alkyl, typically by heating in the presence of a base, such as sodium methoxide.
Compounds of formula (XXXIII) may be prepared by reducing a corresponding C1_4 alkyl ester using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C. The ester, may be prepared by esterifying the corresponding carboxylic acid using, for example, the appropriate alcohol and HC1 or by reducing the corresponding p-nitro compound, for example, by catalytic hydrogenation. Both the acid and the p,-nitro compound may be prepared from the corresponding g-nitroaminoacid, the acid by N-alkoxycarbonylation using, for example, RSOCOCl where RS is as hereinbefore def fined, followed by reduction of the nitro group, for example, by catalytic hydrogenation, or by reduction of the nitro group followed by N-alkoxycarbonylation, and the g-nitro compound by N-alkoxycarbonylation (as for the acid) followed by esterification using, for example, the appropriate alcohol and HC1, or by esterification followed by N-alkoxycarbonylation. The g-nitroaminoacid may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature, for example, by p,-nitration of the corresponding aminoacid using, for example, c.H2S02/c.HN03 at 0°C .
p-Nitro compounds of formula (V) may be prepared by reacting a compound of formula (VI) H(R)N . ~ N~2 HX (vI ) (CH ) 2n wherein n, R and X are as hereinbefore defined, with a compound of formula (VII) / L (VII) Y =C~
L' wherein Y is as hereinbefore def fined and L and L' , which may be the same or different, are suitable leaving groups, for example, chlorine, ethoxy, trichloromethyl, trichloromethoxy, or imidazoyl, for example, in the case where L - L' - chlorine, in a non-polar solvent, such as toluene, in the presence of a base, for example, potassium hydroxide.
- IS -Compounds of formula (VI) may be prepared by ring-opening a compound of formula (V), for example, by refluxing in 2N aqu. KOH.
Compounds of formula (VI) may be prepared by esterification of the corresponding carboxylic acid, typically by treatment with thionyl chloride and an appropriate alcohol at -10°C. followed by reduction of the ester using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C. The acid may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature, for example, by p-nitration of the corresponding aminoacid using, for example, c.H2S04/c.HN03 at 0°C .
Compounds of formula (III) and (VII) may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature.
p-Nitro compounds of formula (V) may also be prepared by g-nitration of a compound of formula (XXXVI) (XXXVI ) CH ~ .
2~n wherein n and W are as hereinbefore defined using, for example, c.H2S02/c.HN03 at 0°C.
Compounds of formula (XXXVI) may be prepared by reacting a compound of formula (XXXVII) H(R)N
HX (XXXVII) (CH ) 2n wherein n, R and X are as hereinbefore defined, with a compound of formula (VII) wherein Y, L and L' are as hereinbefore defined, typically in the presence of a base, for example, potassium hydroxide in a non-polar solvent, such as toluene.
Compounds of formula (XXXVII) may be prepared by reducing the corresponding nitro compounds, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent, such as ethanol. The nitro compound corresponding to the compound of formula (XXXVII) may be prepared by reacting a compound of formula (XXIV) (XXIV) 2 n+1 wherein n is as hereinbefore defined, with paraformaldehyde in a polar aprotic solvent, such as DMF, in the presence of a base, for example, sodium methoxide, at 0°C, or by esterification of the corresponding carboxylic acid, 'typically by treatment with thionyl chloride and an appropriate alcohol at -10°C., followed by reduction of the ester group using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C.
The compound of formula (XXIV), the acid and the aldehyde may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature.
Compounds of formula (I) may also be prepared by reacting a compound of formula (XV) wherein n, R, X and Z are as hereinbefore defined, with a compound of formula (VII) wherein Y, L and L' are as hereinbefore defined, for example, in the case where L = L' = ethoxy, by heating in the presence of a base, for example, potassium carbonate.
Compounds of formula (XV) may be prepared by ring-opening a compound of formula (I) wherein n, Z and W are as hereinbefore defined in which R, X and Y are as hereinbefore defined, for example, by refluxing in 2N
aqu. KOH.
Compounds of formula (XV) may be prepared by esterification of the corresponding carboxylic acid, typically by treatment with thionyl chloride and an appropriate alcohol at -10°C., followed by reduction of the ester using, for example, sodium borohydride, in a polar solvent system, such as ethanol/water, at 0°C. The acid may be prepared by ring-opening a compound of formula (XVI) H
NR ~ N
XVI
( >
R N
(CH2)n .
Z
O
wherein n, R and Z are as hereinbefore defined and R6 is hydrogen or benzyl, typically by refluxing in water in the presence of a base, for example, barium hydroxide.
Compounds of formula (XVI ) wherein n = 1 may be prepared by reducing a compound of formula (XVII) H
R
O N / CH ~ (XVI I ) (CH
R6 2)n_1 Z
N
O
wherein n, R, R6 and Z are as hereinbefore defined, typically by catalytic hydrogenating using, for example, Pd/C in a polar solvent system, such as ethanol/water.
Alternatively, an enantioselective reducing agent, such as Rh(cod)(dipamp) -BF2 (JCS. Chem. Comm. 275 (1991)), may be used to reduce the double bond and thereby introduce a chiral centre at the 4-position of the dioxoimidazole ring.
Compounds of formula (XVII) may be prepared by reacting a compound of formula (XVIII) H
(xvIII) OHC ~
{CH2)n-1 Z
wherein n and Z are as hereinbefore defined, with, in the case where R6 is to be hydrogen, a compound of formula (X) wherein R is as hereinbefore defined, typically by heating in glac. acetic acid in the presence of ammonium acetate.
Compounds of formula (XVIII) may -be prepared by the reduction hydrolysis of the corresponding nitrile, typically using Raney nickel and sodium hypophosphite in a mixture of water, acetic acid and pyridine.
Compounds of formula (XVI) wherein R6 is benzyl may be prepared by reacting a compound of formula (XXXV) NR ~ NHNH2 (xxxv) Bz ~ (CH2)~
O
wherein n and R are as hereinbefore defined, with a compound of formula (III) wherein L is as hereinbefore defined, typically using the reaction conditions described above for the reaction of (II) with (III).
Hydrazines of formula (XXXV) may be prepared from the corresponding aniline, typically using the reaction conditions described above for the conversion of (IV) to (II). The aniline may be prepared by reducing the corresponding g-nitro compound, typically using the reaction conditions described above for the conversion of (V) to (IV). The g-nitro compound may be prepared by reacting the corresponding p-nitroaminoacid with benzyl isocyanate in the presence of base, for example, potassium hydroxide, in a polar solvent, such as water.
The p-nitroaminoacid may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature, for example, by ~-nitration of the corresponding aminoacid using, for example, c . H2S04/c . HN03 at 0°C .
Compounds of formula (XV) may be prepared by reducing a compound of formula (XX) H
02N ~ N .
(xx) HX
(CH2)n Z
wherein n, X and Z are as hereinbefore defined, typically by catalytic hydrogenation using, for example, Pd/C in a polar solvent, such as ethanol.
Compounds of formula (XX) may be prepared by reacting a compound of (XXI ) H
N
02N w (CH2)n+1 Z (xxI) wherein n and Z are as hereinbefore defined, with paraformaldehyde in a polar aprotic solvent, such as DMF, in the presence of a base, fo,r example, sodium methoxide, at 0°C .
Compounds of formula (XXI) may be prepared by reacting a compound of formula (XXII) H
(xxll) ~2N ~ CH
2~n+1 wherein n is as hereinbefore defined, with, the appropriate compound of formula (XXVIII) wherein R3 is as hereinbefore defined, typically by heating in glac.
acetic acid.
Compounds of formula (XXII) wherein n = 1 may be prepared by reducing a compound of formula (XXIII) H
N (XXIII) ~2N~CH iCH~
(CH2)n-1 wherein n is as hereinbefore defined, using, for example, sodium borohydride and 40% w/v aqu. NaOH in a polar aprotic solvent such as acetonitrile, at 0°C.
Compounds of formula (XXIII) may be prepared by heating the appropriate aldehyde with nitromethane in the presence of ammonium acetate. The aldehyde may be prepared from a compound of formula (XIX) wherein n is as hereinbefore defined using the reaction conditions described above for preparing a compound of formula (XVIII) from the corresponding nitrile.
Compounds of formula (XXII) where n - 1 may be obtained commercially or prepared from readily available starting materials by methods known to those skilled in the art or obtainable from the chemical literature.
Compounds of formula (XXI) wherein n - 1 may also be prepared from a compound of formula (XXXIX) H
. ~ N
(XXXIX) ~2N ~ CH ~ CH ~ CH
2~n-1 Z
wherein n and Z are as hereinbefore defined, using reaction conditions analogous to those used to convert (XXIII) to (XXII). Compounds of formula (XXXIX) may be prepared from a compound of formula (XVIII) wherein n and Z are as hereinbefore defined using reaction conditions analogous to those used to prepare (XXIII) from the appropriate aldehyde and nitromethane.
Compounds of formula (I) may also be prepared from a compound of formula (XXXI) H
N
W ' / (xxxl ) (CH2)n wherein n and W are as hereinbefore defined, by methods known to those skilled in the art or obtainable from the chemical literature, for example, by treatment with (COL)2, where L is a suitable leaving group, for example, chlorine, to give the corresponding 3-COCOL compound which may then be treated with HNR1R2, where R1 and Rz are as hereinbefore defined, and reduced using, for example, lithium aluminium hydride. Alternatively, the compound of formula~(XXXI) may be treated with CH20/KCN to give the corresponding 3-cyanomethyl compound which may then be catalytically hydrogenated over Raney nickel in the presence of NHR1R2 as hereinbefore defined.
The aforementioned 3-cyanomethyl compound may also be prepared by cyclising a compound of formula (XXXX) I NHN = CH(CH2)2CN
i W \ ~CH2~n ~ cxxr~p wherein n and W are as hereinbefore defined, typically by refluxing in an aprotic solvent, such as chloroform, in the presence of polyphosphate ester.
Compounds of formula (XXXX) may be prepared by reacting a compound of formula (II) wherein n and W are as hereinbefore defined with 3-cyanopropanal, or a carbonyl-protected form thereof, such as (the diethyl acetal, typically in an aqueous acid, for example, dil. HC1.
Compounds of formula (XXXI) may be prepared by reducing a compound of formula (XXXII) H
(XXXII) W
~ (CH2)n SPh wherein n and W are as hereinbefore defined, typically by heating with Raney nickel in a polar solvent, such as IPA.
Compounds of formula (XXXII) may be prepared by reacting a hydrazine of formula (II) wherein n and W are as hereinbefore defined with phenylthioacetaldehyde, or a carbonyl-protected form thereof, for example, the diethyl acetal, in a polar solvent, such as acidified ethanol.
For a better understanding of the invention, the following Examples are given by way of illustration.
SYNTHETIC AND REFERENCE EXAMPLES
Synthetic Example 1 Preparation of (S)-2-f5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine (a) (S)-Methyl 4-nitrophenvlalanate hydrochloride Methanol (110m1) was treated dropwise with thionyl chloride (26.3g) at -10°C and L-4-nitrophenylalanine (Fluka, 21.7g) added to the resulting solution as a solid. The mixture was stirred overnight at room temperature and the methanol removed in vacuo to give the desired product as a pale yellow solid (21.2g) .
(b) (S)-2-Amino-3-(4-nitrophenyl)propanol The product from step (a) (21.2g) was dissolved in ethanol/water (190m1, 100/90 v/v) and the solution added dropwise at 0°C to a stirred solution of sodium borohydride (l3.Og) in ethanol/water (190m1, 100/90 v/v). The resulting mixture was refluxed for 2.5 hours, cooled and the precipitate filtered off.
The ethanol was partially removed from the filtrate in vacuo and the resulting precipitate filtered off and dried to give the desired product as a pale yellow solid (7.5g).
(c) (S)-4-(4-Nitrobenzyl)-1,3-oxazolidin-2-one The product from step (b) (4.9g) was suspended in toluene, the suspension, cooled to 0°C and a solution of potassium hydroxide (7.Og) in water (56m1) added dropwise. A solution of phosgene (62.5m1 of a 12%
w/v solution in toluene) was added dropwise to the resulting solution over 30 minutes and stirring continued for 1 hour. The mixture was extracted with ethyl acetate and the extracts washed with brine, dried and evaporated in vacuo to give a yellow oil. Crystallisation from ethyl acetate gave the desired product as pale yellow crystals (2 . 3g) .
(d) (S)-4-(4-Aminobenzyl)-1,3-oxazolidin-2-one hydro-chloride A suspension of the product from step (c) (0.79g) and 10% palladium on carbon (0.26g) in a mixture of ethanol (15m1), water (llml), ethyl acetate (2.Om1) and aqu. 2N HC1 (2.3m1) was stirred under 1 atmos.
pressure of hydrogen until uptake ceased. The mixture was filtered through Hyflo (Trade-mark) and the filtrate evaporated in vacuo to give the desired product as a pale yellow foam (0.79g).
(e) (S)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride The product from step (d) (0.79g) was suspended in water (4.8m1) and c.HCl (8.lml) added dropwise. The resulting mixture was cooled to -5°C and a solution of sodium nitrite (0.24g) in water (2.4m1) added dropwise to the stirred mixture. over 15 minutes followed by 30 minutes stirring at -5 to 0°C. The solution was then added at 0°C over 15 minutes to a stirred solution of tin (II) chloride (3.Sg) in c.HCl (6.9m1), followed by 3 hours stirring at room temperature. The solution was evaporated in vacuo and the residue triturated with ether to give the desired product as a pale yellow solid (0.96g).
(f) (S)-2-f5-(2-Oxo-1 3-oxazolidin-4-ylmethyl)-1H-indol-3_yllethylamine The product from step (e) (0.84g) was dissolved in ethanol/water (125m1, 5:1) and the solution treated with 4-chlorobutanaol dimethylacetal (JACS 1365 (1951), 0.52g). The mixture was refluxed for 2 hours, the solvent removed in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant. The desired product was obtained as a colourless oil (0.21g).
Salt of Synthetic Example 1 Maleate Ethanolic malefic acid (1.0 equiv.) was added dropwise to the free base (0.21g) and the ethanol evaporated in vacuo. The resulting gum was freeze-dried from water to give the desired product as a white lyopholate (0.22g), [a] 21D -5. 92° (c = 0.3, MeOH) .
1H NMR (DMSO-d6, b) : 2.7-3.5 (6H, m, CH2) , 3.35 (2H, s, NHz) , 4.05 (2H, m, CHZ) , 4.25 (1H, m, CH) , 6.05 (2H, s, malefic acid) , 6.98 (1H, d, Ar) , 7.2 (1H, s, Ar) , 7.3 (1H, d, Ar), 7.4 (1H, s, Ar), 7.75 (1H, s, NH) and 10.9 (1H, s , NH ) .
Microanalysis: C 55.03 (54.96), H 5.54 (5.85), N 10.30 (10.68) .
Synthetic Example 2 Preparation of (S)-N N-dimethYl-2-f5-(2-oxo-1,3-oxazoli-din-4-ylmethyl)-1H-indol-3-yllethylamine 0.9 isoprot~anol-ate 0.5 hydrate A solution of formaldehyde (0.03g) in methanol (1.8m1) was added to a solution of the free base from step (f) of Synthetic Example 1 (0.12g) and sodium cyanoborohydride (0.04g) in a mixture of methanol (5.5m1) and glac. acetic acid (0.14g) and the resulting mixture stirred overnight at room temperature. The pH was adjusted to 8.0 using aqu. KZC03 and the mixture extracted with ethyl acetate.
The combined extracts were washed with brine, dried and evaporated to give a colourless oil (0.14g) which crystallised from isopropanol to give the desired product as a white crystalline solid (O.lOg), mp 139-141°C.
1H NMR (DMSO-ds, 8) : 2.2 (6H, s, NMe2~, 2.5 (2H, m, CHZAr) , 2 .7-3 . 0 (4H, m, CHz) , 4.1 (2H, m, CH2) , 4.3 (1H, m, CH) , 6.9 (1H, d, Ar), 7.1 (1H, s, Ar), 7.3 (1H, d, Ar), 7.4 (1H, s, Ar) , 7.7 (1H, s, NHCO) and 10.7 (1H, s, NH) .
Microanalysis: C 64.26 (64.11), H 8.28 (8.34), N 12.02 (12.00) [a] 22D - 5 . 79° (c = 0 . 5, MeOH) Salts of Synthetic Example 2 Maleate A solution of malefic acid (0.17g) in ethanol (5m1) was added to a solution of the free base (0.5g) in ethanol (5m1). The mixture was evaporated in vacuo and the resulting oil triturated with ether and methanol to give the maleate salt as a white solid which was recrystallised from ethanol (0.45g), mp 151-152°C.
Hydrochloride Ethereal HC1 (1.1 equivs.). was added dropwise to a stirred solution of the free base (0.35g) in methanol (lml) at 0°C. The hydrochloride salt precipitated as an oil. The mixture was evaporated in vacuo and the resulting foam crystallised from isQpropanol to give the desired product as a white solid (0.36g), mp 118-120°C, [a] 23D -9 . 35 (c = 0 . 31, water) .
Succinate A solution of succinic acid (0.36g) in ethanol (lOml) was added to a solution of the free base (l.Og) in ethanol (lOml). The mixture was evaporated in vacuo and the resulting foam triturated with isopropanol to give the succinate salt as a white solid (l.Og), mp 122-123°C.
Benzoate A solution of benzoic acid (0.37g) in ethanol (lOml) was added to a solution of the free base (l.Og) in ethanol (lOml). The mixture was evaporated in vacuo and the resulting foam crystallised from ethyl acetate to give the benzoate salt as a white solid (0.74g), mp 90-92°C.
Synthetic Example 3 Alternative preparation of (S)-N N-dimethyl-2-f5-(2-oxo-1 3-oxazolidin~lmethyl)-1H-indol-3-yllethylamine 0.9 iso-propanolate 0.5 hydrate 4-Dimethylaminobutanal diethylacetal (Croatica Chemica Acta 36, 103 (1964), 3.9g) was added to a solution of the product from step (e) of Synthetic Example 1 (10.4g) in a mixture of acetic acid (50m1) and water (150m1) and the resulting mixture refluxed for 4.5 hours. The mixture was cooled, evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H (50:8:1) as eluant to give the desired product as a pale yellow oil which crystallised from isopropanol as a white crystalline solid (3.5g), mp 138-140°C. 1H NMR, microanalysis and [a]D as for product of Synthetic Example 2.
Reference Example 4 Preparation of (~)-3-(1-methyl-4-piperidyl)-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indole (a) 3-(1-Methyl-1 2,3,6-tetrahydro-4-pyridyl)-1H-indole-5-carbonitrile 5-Cyanoindol (Aldrich, 20.Og) was added to a solution of KOH (22.4g) in methanol (200m1). N-Methyl-4-piperidone (Aldrich, 40.4g) was then added dropwise and the resulting mixture refluxed for 4 hours, then cooled and poured into water. The resulting precipitate was filtered off and dried to give the desired product as a pale pink crystalline solid (32.6g) .
(b) 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-1H-indole-5-carbaldehyde Raney nickel (ca lOg) was added to a solution of the product from step (a) (5.Og) and sodium hypophos-phite (6.Og) in a mixture of water (25m1), glac.
acetic acid (25m1) and pyridine (50m1) at 45°C.
The resultin mixture was stireed at 45°C for 1 hour, cooled and basified to pH 9 with 0.88 NH40H. The mixture was filtered through Hyflo and the filtrate extracted with chloroform. The combined extracts were dried and evaporated in vacuo to give the desired product as an off-white solid which was recrystallised from ethanol (2.4g).
(c) 5-f3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-1H
indol-5-ylmethylenel-2,4-imidazolidinedione A mixture of the product from step (b) (2.4g), hydantoin (Aldrich, 0.98g) and ammonium acetate (0.74g) in glac. acetic acid (2.4m1) was heated at 120°C for 4 hours. The mixture was cooled and the resulting precipitate filtered off and dried to give the desired product as,a yellow solid (2.4g).
(d) (~) -5- (2 , 5-Dioxo-4-imidazolidinylmethyl) -3- (1-methyl-4-piperidyl)-1H-indole The product from step (c) (2.4g) was suspended in a mixture of water (100m1) and ethanol (200m1) and 10% w/w Pd/C (0.25g) added. The mixture was stirred under 1 atmos. pressure of hydrogen for 17 hours when uptake was complete. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo to give the desired product as a colourless solid (2.4g) .
(e) (~) -3- f3- (1-Methyl-4-piperidyl) -1H-indol-5-yll -alanine A solution of the product from step (d) (2.4g) and barium hydroxide hydrate (8.4g) in water (50m1) was refluxed for 72 hours, then cooled and evaporated in vacuo. The residue was taken up in hot methanol and filtered to remove barium salts. The filtrate was evaporated in vacuo, the residue dissolved in water and dry ice added to precipitate barium carbonate. The latter was filtered off and the filtrate evaporated in vacuo to give the desired product as a yellow foam (1.3g).
(f) (~)-Methyl 3-f3-(1-methyl-4-piperidyl)-1H-indol-5-yllalanate A solution of the product from step (e) (6.2g) in methanol (40m1) was added dropwise to a solution of thionyl chloride (2.9m1) in methanol (35m1) at -10°C. The resulting mixture was stirred overnight at room temperature, then evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H (30:8:1) as eluant. The eluate was evaporated in vacuo to give the desired product as a yellow foam (4.8g) .
(g) (+) -3- [3- (1-Methyl-4-piperidyl) -1H-indol-5-vll -2-amino-1-propanol A solution of the product from step (f) (4.8g) in water (20m1) and ethanol (20m1) was added dropwise to a suspension of sodium borohydride (0.61g) in a mixture of water ( 2 Oml ) and ethanol ( 2 Oml ) at 0°C .
The resulting mixture was refluxed for 3 hours, then evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant. The eluate was evaporated in vacuo to give the desired product as a colourless foam ( 1 . 6g) .
(h) (+) -3- (1-Methyl-4-giperid~l) -5- (2-oxo-1, 3-oxazo-lidin-4-ylmethyl)-1H-indole A mixture of the product from step (g) (1.6g), diethyl carbonate (0.73m1) and potassium carbonate (0.08g) was heated at 130°C for 5 hours. The mixture was cooled, taken up in methanol and the insoluble potassium carbonate filtered off. The filtrate evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant. The eluate was evaporated in vacuo and the residue recrystallised from isopro-panol/ether to give the desired product as a colour-less crystalline solid (l.lg), mp 191-192°C.
1H NMR (DMSO-d6, b) : 1.6-1.8 (2H; 2 x CHNMe) , 2 .8-2 .1 (4H, 2 x CHZ) , 22.2 (3H, s, NMe) , 2.6-3.0 (2H, 2 x CHNMe: 1H, CH: 2H, CHZAr), 3.9-4.1 (2H, m, CH20), 4.2-4.4 (1H, m, CHN), 6.9 (1H, d, Ar), 7.1 (1H, d, Ar), 7.3 (1H, d, Ar), 7.4 (1H, s, Ar), 7.8 (1H, s, NHCO) and 10.7 (1H, S, NH).
Salt of Reference Example 4 Hydrochloride c.HCl (1.0 equiv.) was added dropwise to a stirred solution of the free base (l.lg) in ethanol (5m1) at 5°C.
The addition of ether to the resulting mixture precipitated the desired product as a white solid (l.lg), mp 235-236°C (dec) .
Reference Example 5 Alternative preparation of (+)-3-(1-methyl-4-piperidvl)-5-(1 3-oxazolidin-4-ylmethyl)-1H-indole (a) 1H-Indole-5-carbaldehyde Raney nickel (6.7g) was added to a solution of 5-cyanoindole (Aldrich, lO.Og) and sodium hypophos-phite (20.0 g) in a mixture of water (73m1), glac.
acetic acid (73m1) and pyridine (145m1) at 45°C for 2 hours, then cooled and filtered through Hyflo. The filtrate was diluted with water and extracted with ethyl acetate. The combined extracts were washed with water, 10% aqu. citric acid. 1N aqu. HC1, water and brine, dried and evaporated in vacuo to give the desired product as a buff solid which was recrystallised from chloroform (7.5g).
(b) 5- (2-nitroethen~l) -1H-indole A mixture of the product from step (a) (7.5g), ammonium acetate (1.5g) and nitromethane (77m1) was heated at 110°C for 2 hours, then cooled and evaporated in vacuo. The residue was triturated with water to give the desired product as a yellow solid which was filtered off and dried (9.2g).
(c) 5-(2-Nitroethyl)-1H-indole A solution of sodium borohydride (2.Og) and 40%
w/v aqu. NaOH was added dropwise to a solution of the product from step (b) (1.9g) in acetonitrile (55m1) at 0°C. The pH was maintained at 3-6 by periodic additions of 2N aqu._ HC1. The resulting solution was stirred at 0°C for 2 hours, then diluted with water and extracted with DCM. The combined extracts were washed with brine, dried and evaporated in vacuo to give a yellow oil which was eluted through a silica column using chloroform as eluant to give the desired product as a pale yellow oil (0.78g).
(d) 3~1-Methyl-1, 2 , 3 , 6-tetrahydro-4-wridyl) -5- (2-nitroethyl)-1H-indole N-Methyl-4-piperidone (Aldrich, 4.2g) was added to a solution of the product from step (c) (2.3g) in glac. acetic acid (35m1) at 100°C for 1 hour, cooled and poured into a mixture of 0.88 NH40H
(6lml) and ice (61g). The resulting solid was filtered off, dried and recrystallised from ethanol to give the desired product as a white solid (1.6g) .
(e) (~)-3-f3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-1H-indol-5-yll-2-amino-1-propanol Sodium methoxide (0.30g) was added to a solution of the product from step (d) (1.5g) in DMF (l5ml) at 0°C. To the resulting solution was added dropwise a suspension of paraformaldehyde (0.19g) 9n DMF
(20m1). The resulting mixture was stirred at 0°C
for 1.5 hours, then poured into water and extracted with ethyl acetate. The combined extracts were washed with water and brine, dried and evaporated in vacuo to give a yellow oil which was eluted through a silica column using DCM/EtOH/NH40H
(50:8:1) as eluant to give the desired product as an off-white solid (0.85g which was recyrstallised from ethanol.
(f) (~)-3-f3-(1-Methyl-4-piperidyl)-1H-indol-5-yll-2-amino-1-pro~anol The product from step (e) (0.08g) was dissolved in ethanol (25m1) and 10% w/w Pd/C (0.23g) added. The mixture was stirred under 1 atmos. pressure of hydrogen for 7 hours when uptake was complete. The mixture was filtered through celite and the filtrate evaporated in vacuo to give the desired product as colourless oil which was eluted through a silica column using DCM/EtOH/NH40H (50:8:1) as eluant.
(g) (~)-3-(1-Methyl-4-piperidyl)-5-(1,3-oxazolidin-4-ylmethyl)-1H-indole A mixture of the product from step (f) (1.6g), diethyl carbonate (0.71g) and potassium carbonate (0.08g) was heated at 130°C for 5 hours. The mixture was cooled, taken up in-methanol and the insoluble potassium carbonate filtered off. The filtrate was evaporated in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H
(30:8:1) as eluant to give a colourless foam which was crystallised from isopropanol/ether to give the desired product as a colourless crystalline solid (l.lg), mp 191-192°C. 1H NMR and microanalysis as for product of Reference Example 4.
Synthetic Example 6 Preparation of (R)-2-[5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine (a) (R)-4-(4-nitrobenzyl)-1,3-oxazolidin-2-one A solution of D-4-nitrophenylalanine (Fluka, 53g) in dimethoxyethane (250m1) was warmed to 67°C and BF3.Et20 (Aldrich, 37m1) added over 1 hour. The resulting solution was stirred at 67°C for 1 hour, then heated to 80°C and BH3,Me2S (Aldrich, 40m1) added over 1 hour at 80-85°C. The resulting solution was heated at 85°C for 4 hours, then cooled and methanol (40m1) added. The solution was heated to 85°C and the solvents removed by distillation to 1/3 of the original bulk. 6N aqu. NaOH (136m1) was added to the hot solution which was then heated at 85°C for hour, cooled and DCM (100m1) added. The solution was cooled to -15 to -20°C and a solution of tri-chloromethyl chloroformate (Aldrich, 18.2m1) in DCM
(23m1) added at below -10°C. The pH was maintained at 9-11 by periodic additions of 6N aqu. NaOH. The resulting solution was stirred at room temperature for 1 hour, then diluted with water and extracted with DCM. The combined extracts were washed with water and brine, dried and evaporated in vacuo to give the desired product as a pale brown solid which was recrystallised from ethyl acetate to give a pale yellow solid (35g) , mp 113-115°, [a] 21D +46 .47°
(c = 0.56, MeOH).
(b) (R)-4-(4-Aminobenzyl)-1,3-oxazolidin-2-one hydro-chloride The product from step (a) (lO.Og) was suspended in a mixture of water (120m1), ethanol (60m1) and 2N aqu.
HC1 (22.5m1) and 10% w/w Pd/C (l.Og) added. The mixture was stirred under 1 atmos. pressure of hydrogen for 8 hours when uptake was complete. The mixture was filtered through Hyflo (Trade-mark for a finely divided filtration material) and the filtrate evaporated in vacuo to give the desired product as a colourless glass (10.3g).
(c) (R)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hvdrochloride The product from step (b) (10.3g) was suspended in water (53m1) and c.HCl (106m1) added dropwise. The resulting mixture was cooled to -5°C and a solution of sodium nitrite (3.2g) in water (30m1) added drop-wise to the stirred mixture over 15 minutes followed by 30 minutes stirring at -5 to-OC°. The solution was then added at 0°C over 15 minutes to a stirred solution of tin (II) chloride (51g) in c.HCl (9lml), followed by 3 hours stirring at room temperature.
The solution was evaporated in vacuo and the residue triturated with ether to give the desired product as a pale yellow solid (llg).
(d) (R)-2-(5-(2-Oxa-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl)-ethylamine The product from step (c) (8.8g) was dissolved in ethanol/water (500m1, 5:1 v/v) and the solution treated with 4-chlorobutanal dimethylacetal (J.
Amer. Chem. Soc. 1365 (1951), 5.5g). The mixture was refluxed for 2 hours, the solvent removed in vacuo and the residue eluted through a silica column using DCM/EtOH/NH40H (30:8:1 v/v/v) as eluant. The desired product was obtained as a pale yellow oil (0.6og) .
Salt of Synthetic Example 6 Hydrochloride c.HCl (0.06m1) was added dropwise to a stirred solution of the free base (0.16g) in ethanol (2m1) at 0°C. The hydrochloride salt was precipitated.as a fawn solid, mp 269-271°C, [a] Z1D t5. 88° (c = 0 .27, MeOH) .
Synthetic Example 7 Preparation of (R)-N N-dimethyl-2-f5-(2-oxo-1,3-oxazoli-din-4-ylmethyl)-1H-indol-3-yllethylamine A solution of 35% w/v aqu. formaldehyde (0.3m1) in methanol (2.Om1) was added to a solution of the product from step (d) of Synthetic Example 6 (0.44g) and sodium cyanoborohydride (0.13g) in a mixture of methanol (8.5m1) and glac. acetic acid (0.51g) at 10°C and the resulting mixture stirred at room temperature for 2.5 hours. 2N
aqu. NaOH (l.3ml) was added, then sodium borohydride (0.19 g) followed by 2N aqu. HCl (1.3 ml) . The methanol was evaporated in vacuo and the remaining solution diluted with water, taken to pH 7 with solid potassium carbonate and washed with ethyl acetate. Further potassium carbonate was added to Ph 11 and the solution extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give the desired product as a white foam (0.45g) .
Salt of Synthetic Example 7 Hydrochloride c.HCl (0.16m1) was added dropwise to a stirred solution of the free base (0.45g) in ethanol (4.5m1 at 0°C. The mixture was evaporated in vacuo and the resulting foam triturated with ethyl acetate to give the desired product as a white solid, mp 130°C, [a] Z1D +5 . 15° (c = 0 . 77, MeOH) .
Reference Example 8 Preparation of (S)-N,N-dimethyl-2-f5-(2-thia-1,3-oxazo-lidin-4-~lmethyl)-1H-indol-3-~rllethylamine hydrochloride (a) (S)-N N-Dimethyl-2-[5-(2-amino-1-propanol)-1H-indol-3-yllethy-lamine A solution of the hydrochloride salt of the product of Synthetic Example 2 (0.33g) in 2N aqu. KOH (lOml) was refluxed for 4 hours, then cooled and extracted with ethyl acetate. The combined extracts were dried and evaporated in vacuo to give the desired product as a colourless oil (0.25g).
(b) ~S)-N N-Dimethyl-2-f5-(2-thia-1,3-oxazolidin-4-yl methyl)-1H-indol-3-yllethylamine hydrochloride A solution of N,N'-thiocarbonylimidazole (Aldrich, 0.21g) in THF (4m1) was added dropwise to a stirred solution of the product from step (a) (0.31g) in THF (4ml) and the mixture refluxed for 23 hours, then cooled and evaporated in vacuo. The residue was chromatographed through a silica column using DCM/EtOH/NH40H (20:8:1) as eluant to give the desired product as a colourless oil.
Salt of Reference Example 8 Hvdrochloride 1M Ethanolic HC1 (1.0 equiv.) was added dropwise to the free base and the ethanol evaporated in vacuo. The resulting gum was freeze-dried from water to give the desired product as a white solid (0.17g), mp 133-136°C, (softens 183°C) , [a] 24.sD -29.8 (c = 0 . 5 , water) .
Reference Example 9 Preparation of (S)-2-f5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yllethylamine hydrobromide (a) ~S)-3-Methyl-4-(4-nitrobenzyl)-2-oxazolidinone Sodium hydride (0.808 as a 60% w/w dispersion in oil) was added at room temperature to a stirred solution of the product from step (c) of Synthetic Example 1 (4.4g) in dry THF (150m1). The mixture was stirred for 1.5 hours, then dimethyl sulphate (2.1m1) was added and stirring continued for a further 16 hours. More sodium hydride (0.40g) was added and stirring continued for another 2 hours.
The mixture was evaporated in vacuo and the residue suspended in ethyl acetate and filtered. The filtrate was evaporated in vacuo and the residue crystallised from ethyl acetate/hexane to give the ' desired product as yellow crystals (3.7g), mp 146-147°C, [a] 23D +64 .5° (c = 1 . 0, MeOH) .
(b) (S)-3-Methyl-4-(4-aminobenzyl)-2.-oxazolidinone hydrochloride A suspension of the product from step (a) (4.Og) and 10% w/w Pd/C (0.20g) in a mixture of ethanol (70m1) and dil. HCl (2N aqu. HC1 (12m1) + water (55m1)) was hydrogenated at 45 psi for 1 hour.
The mixture was filtered through Hyflo and the filtrate evaporated in vacuo to give the desired product as a foam.
(c) (S)-3-Methyl-4-(4-hydrazinobenzyl)-2-oxazolidinone hydrochloride A solution of the product from step (b) (4.1g) in water (24m1) was cooled to -5°C and c.HCl (40m1) added. A solution of sodium nitrate (1.2g) in water (12m1) was then added and stirring continued for 0.5 hour. The resulting solution was added dropwise at -5°C to a stirred solution of stannous chloride dehydrate (18.8g) in c.HCl (34m1). The resulting mixture was stirred at 0°C for 2.5 hours, then evaporated in vacuo. The residue was taken up in water, brought to pH 2.5 using lON aqu. NaOH and filtered. The filtrate was evaporated in vacuo and the residue triturated with ethanol and filtered.
The filtrate was evaporated in vacuo to give the desired product as a froth.
(d) (S)-2-[5-(3-Methyl-2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol-3-yl]ethylamine hydrobromide 4-Chlorobutanal dimethylacetal (J. Amer. Chem. Soc.
1365 (1951) 2.3g) was added to a stirred solution of the product from step (c) (4.4g) in ethanol/-- water (150m1/20m1) and the mixture refluxed for 2 hours. The cooled mixture was evaporated in vacuo, and the residue eluted through a silica column using DCM/MeOH/NH40H (60:8:1) as eluant to give a brown oil (1.7g). A portion of this (0.25g) was taken up in ethanol and treated with an excess of HBr in acetic acid (ca 45% w/v). The resulting solution was evaporated in vacuo and the residue triturated with ether, then crystallised from ethanol/hexane to give the desired product as pale yellow crystals (0.14g), mp 203-205°C, [a] z5D +29. 9° (c = 0. 5, MeOH) .
Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 10 Preparation of (S)-N,N-dimethyl-2-[5-(3-methyl-2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yllethylamine maleate 0.75 hydrate Sodium cyanoborohydride (0.14g) followed by glac. acetic acid (0.54m1) were added at room temperature to a stirred solution of the free base (0.52g) from step (d) of Reference Example 9 in methanol (9.Om1). When effervescence was complete, a solution of 37% w/v aqu.
formaldehyde (0.16g) in methanol (2.Om1) was added and the mixture stirred for 1 hour, then diluted with water, saturated with potassium carbonate and extracted with ethyl acetate. The combined extracts were evaporated in vacuo and the residue eluted through a silica column using DCM/MeOH/NH40H (60:8:1) as eluant to give the free base of the desired product as a colourless oil (0.25g).
The latter was dissolved in ethanol (lOml), treated with a solution of malefic acid (0.09g) in ethanol (lml) and the resulting solution evaporated in vacuo to give an oil which was triturated with ether, the freeze-dried from water to give the desired product as a colourless glass, [a] ZZD +24 . 5° (c - 0 . 5, MeOH) . Elemental analysis, 1H NMR
and MS were consistent with the proposed structure.
Synthetic Example 11 Preparation of (S)-N-benzyl-2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl)ethylamine maleate 0.75 hydrate Benzaldehyde (0.70g) was added at room temperature to a stirred solution of the compound of. Synthetic Example 1 (1.7g) in ethanol (20m1). The solution was stirred for 36 hours, then sodium borohydride (0.25g) was added in portions and stirring continued for a further 2 hours.
The solution was evaporated in vacuo and the residue cooled, acidified with 2N aqu. HC1, basified with sodium bicarbonate, saturated with potassium carbonate and extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give an oil which was eluted through a silica column using DCM/EtOH/NH40H (100:8:1) as eluant to give the free base of the desired product as a yellow froth (1.6g). A portion of this (0.13g) was dissolved in ethanol (lOml), treated with a solution of malefic acid (43mg) in ethanol (lml) and the resulting solution evaporated in vacuo. The residue was freeze-dried from water to give the desired product as a pale yellow powder (0.16g) [a]24D +1.4° (c - 0.5, MeOH).
Elemental analysis, 1H NMR and MS were consistent with the proposed structure.
Synthetic Example 12 Preparation of (S)-N-benzyl-N-methyl-2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl)ethylamine maleate hydrate Anhy. potassium carbonate (0.34g), was added at room temperature to a solution of the free base of Synthetic Example 11 (0.45g) in DMF (8.Om1). The suspension was stirred for 0.5 hour, then a solution of dimethyl sulphate (0.17g) in DMF (2.Om1) was added and stirring continued for a further 3 hours. Water (40m1) was added and the mixture extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give a yellow oil which was eluted through a silica column using DCM/EtOH/NH40H (100:8:1) as eluant to give the free base of the desired product as a colourless oil (0.32g). A
portion of this (73mg) was dissolved in ethanol (lOml), treated with a solution of malefic acid (23mg) in ethanol (lml) and the resulting solution evaporated in vacuo.
The residue was freeze-dried from water to give the desired product as a pale yellow powder, [a]24D +3.1° (c -0.5, MeOH). Elemental analysis, 1H NMR and MS were consistent with the proposed structure.
Synthetic Example 13 Preparation of (S)-N-methyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yllethylamine maleate 0.5 hydrate A suspension of the free base of the product of Synthetic Example 12 (0.25g) and 10% w/w Pd/C (O.lOg) in ethanol (25m1) was hydrogenated for 16 hours. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was eluted through a silica column using DCM/EtOH/NH40H (30:8:1) as eluant to give the free base of the desired product (0.14g). The latter was dissolved in ethanol (lOml), treated with a solution of malefic acid (0.06g) in ethanol (lml) and the resulting solution evaporated in vacuo. The residue was freeze-dried from water to give the desired product as a hygroscopic solid, [a] 25D -5 .4° (c - 0 . 5, MeOH) .
Elemental analysis and 1H NMR were consistent with proposed structure.
Reference Example 14 Preparation of (S)-3-(1-methyl-1,2,3,6-tetrahydro-4-gyridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole 0.33 methanolate 0.75 hydrate (a) (S)-3-Phenylthio-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indole Phenylthioacetaldehyde diethylacetal (JCS. Chem.
Comm. 924 (1978), 9.1g) was added at room temperature to a stirred solution of the product from step (e) of Synthetic Example 1 (9.8g) in a mixture of ethanol (150m1) and water (100m1).
c.HCl (5 drops) was added and the mixture stirred at room temperature for 2 days, then partially evaporated in vacuo. The resulting aqueous sus-pension was extracted with ethyl acetate,and the combined extracts washed with water and evaporated in vacuo to give a brown oil. The latter was eluted through a silica column using DCM/EtOH/NH40H
(150:8:1) as eluant to give the desired product as a pale yellow oil (5.Og).
(b) (S)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole Raney nickel (3.Og) was added to a solution of the product from step (a) (3.1g) in IPA (150m1) and the suspension refluxed for 1 hour. More Raney nickel (2.Og) was added and refluxing continued for a further 2 hours. The suspension was filtered hot through Hyflo and the filtrate evaporated in vacuo to give an oil. the latter was eluted through a silica column using ethyl acetate as eluant to give the desired product as a froth (1.3g). 1H NMR and MS
were consistent with the proposed structure.
(c) (S)-3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1 3-oxazolidin-4-ylmethyl)-1H-indole 0.33 methanolate 0.75 hydrate 1-Methyl-4-piperidone (0.478, Aldrich) was added to a stirred solution of the product from step (b) (0.30g) in glac. acetic acid (2.Om1) and the mixture stirred at 100°C for 2 hours. The cooled mixture was poured onto ice/NH40H (20m1) and the resulting solid filtered off. The latter was eluted through a silica column using DCM/EtOH/NH40H
(60:8:1) as eluant and crystallised from ethyl acetate to give the desired product as a colour-less solid (O.llg) , mp 225-227°C, [a,] 2°D -45.4° (c =
0.5. 1N aqu. HC1). Elemental analysis and 1H NMR
were consistent with the proposed structure.
Reference Example 15 Preparation of (S)-3-(1-methyl-4 ~iperidyl)-5-oxo-1,3-oxazolidin-4-ylmeth~rl)-1H-indole hydrobromide A suspension of the product of Reference Example 14 (0.35g) and 10% w/w Pd/C (O.lOg) in a mixture of methanol (lOml), water (lOml) and 1N aqu. Hcl was hydrogenated for 5 hours. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was basified with NH40H, evaporated in vacuo and eluted through a silica column using DCM/EtOH/NH40H (45:8:1) as eluant to give an oil. The latter was taken up in ethanol (5.Oml) and treated with an excess of HBr in acetic acid (ca 45%
w/v) to give the desired product as colourless crystals (0 .20g) , mp 260-261°C [a] Z1D -5.2° (c - 0.5, water) .
Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 16 Preparation of (R)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol hydrate (a) (R)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride By steps identical to steps (a) to (c) of Synthetic Example 6, D-4-nitrophenylalanine was converted to -Sg-(R)-4-(4-hydrazinobenzyl)-2-oxazolidinone hydro-chloride.
(b) (R)-3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1,3-oxazolidin-4-yl)-1H-indole hydrate By steps analogous to steps (a) to (c) of Reference Example 14, the product from step (a) was converted to (R)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole hydrate, mp 229-231°C, [a]1aD +24.9° (c = 0.5. 1N aqu. HCl).
Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 17 Preparation of (R)-3-(1-methyl-4-piperidyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole hydrobromide.
By a method analogous to that of Reference Example 15, the product of Synthetic Example 16 was converted to (R)-3-(1-methyl-4-piperidyl)-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indole hydrobromide, mp 260-261°C, [a]19D +4.6°
(c - 0.5, water). Elemental analysis and 1H NMR were consistent with the proposed structure.
Reference Example 18 Preparation of (R)-3-(1-benzyl-1 2 3 6-tetrahydro-4-wridyl)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole hydrate 1-Benzyl-4-piperidone (Aldrich, 2.8g) was added to a stirred suspension of (R)-5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indole (l.Og), the immediate precursor of the product of Reference Example 16, in glac. acetic acid (20m1) and stirred at 100°C for 3 hours. The cooled mixture was evaporated in vacuo and the residue taken up in methanol, basified with NH40H and evaporated in vacuo to give a dark tar. The latter was eluted through a silica column using DCM/EtOH/NH40H (100:8:1) as eluant and treated with DCM. The resulting precipitate was filtered off to give the desired product as yellow crystals (0.25g), mp 169-170.5°C. Elemental analysis and 1H NMR
were consistent with the proposed structure.
Reference Example 19 Preparation of (R) -3- (4-piperidyl) -5- (2-oxo-1 3-oxazo-lidin-4-ylmethyl)-1H-indol hydrobromide A suspension of the product from Reference Example 18 (0.25g) and 10% w/w Pd/C (O.TOg) in methanol (25m1) was hydrogenated at 90 psi for 20 hours when uptake ceased.
The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was eluted through a silica column using DCM/EtOH/NH40H (30:8:1) as eluant to give an oil. The latter was taken up in IPA and treated with an excess of HBr in acetic acid (ca 45% w/v) to give a hygroscopic solid which was freeze-dried from water to give the desired product as a pale brown powder.
Elemental analysis and 1H NMR were consistent. with the proposed structure.
Reference Example 20 Preparation (~)-N,N-dimethyl-2-f5-(1-thio-2-thia-3-oxazo-lidin-4-ylmethyl)-1H-indol-3-yl]ethylamine acetate Carbon disulphide (90,1) was added to a stirred solution of the product from step (a) of Reference Example 8 (0.31g) and potassium hydroxide (0.08g) in ethanol (3.8m1) and the mixture refluxed, then evaporated in vacuo. The residue was extracted with ether, acidified and chromatographed using a silica reverse phase HPLC
column and eluting with 10-a90% v/v water/acetonitrile with O.1M aqu. ammonium acetate buffer at pH 4.0 over 20 minutes to give the desired product (O.Olg) and, after treatment with HCl, the product of Reference Example 8 (O.llg) . Both were freeze-dried from water and gave 1H
NMR and MS which were consistent with the proposed structures.
Synthetic Example 21 Preparation of (~)-N,N-dimethyl-2-f5-(2-oxo-2 3-oxazo-lidin-5-vlmethyl)-1H-indol-3-yllethylamine hydrochloride (a) (~)-1-Nitromethyl-2=phenylethanol Sodium methoxide (l.lg) was added to a stirred solution of nitromethane (Aldrich, 12.2g) in methanol (100m1) at 0°C and the mixture stirred for minutes. A solution of phenylacetaldehyde (Aldrich, 24.Og) in methanol (50m1) was added drop-wise over 15 minutes and the mixture stirred for 45 minutes at 0°C, then brought to room temperature over 1 hour and stirred overnight. The mixture was evaporated in vacuo and the residue taken up in water and extracted with ether. The combined extracts were washed with water and brine and evaporated in vacuo to give the desired product as a yellow oil (29.Og).
(b) (~)-1-Aminomethyl-2-phenvlethanol hydrochloride A suspension of the product from step (a) (lO.Og) and 10% w/w Pd/C (l.Og) in ethanol (250m1) was hydrogenated until uptake ceased. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo. The residue was taken up in ethyl acetate and extracted with 2N aqu. HC1. The combined extracts were washed with ethyl acetate, then evaporated in vacuo to give the desired product as a pinkish white solid (6.8g).
(c) (~)-5-Benzyl-1,3-oxazolidin-2-one A solution of KOH (9.4g) in water (85m1) was added to a stirred solution of the product from step (b) (5.1g) in toluene (150m1) at 0°C. A solution of phosgene (9.8g) in toluene (78.4m1 - 12.5% w/v) was added dropwise over 15 minutes and the mixture brought to room temperature, then stirred overnight.
The aqueous phase was separated and extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give the desired product as a white solid (2.2g), mp 106-108°C. Elemental analysis was consistent with the proposed structure.
(d) (~) -5- (4-Nitrobenzyl) -1, 3-oxazolidin-2-one c.H2S04 (1.6m1) was added to the product from step (c) at 0°C followed by c.HN03 (0.33m1, ca 0.05m1/5 minutes) also at 0°C. The mixture was stirred for 0.5 hour at 0°C and then for 0.5 hour at room temperature. Water/ice (100m1) was added and the mixture extracted with ethyl acetate. The combined extracts were evaporated in vacuo to give a yellow oil which was recrystallised from ethyl acetate to give the desired product as a white powder (0.4g), mp 143-146°C.
(e) (~)-5-(4-Aminobenzyl)-1,3-oxazolidin-2-one hydro-chloride A suspension of the product from step (d) (1.4g) and 10% w/w Pd/C (0.14g) in a mixture of water (21m1), ethanol (28m1) and 2N aqu. HCl (3.2m1) was hydro-genated for 2 hours when uptake ceased. The mixture was filtered through Hyflo and the filtrate evaporated in vacuo to give the desired product as a pale yellow foam (1.4g).
(f) (~)-N,N-Dimethvl-2-f5-..(.2-oxo-1,3-oxazolidin-5-ylmethyl)-1H-indol-3-yllethylamine hydrochloride c.HCl (14.5m1) was added to a stirred solution of the product from step (e) (1.4g) in water (8.5m1) at 0°C. A solution of sodium nitrite (0.43g) in water (4.3m1) was added dropwise over 15 minutes at 0°C and the mixture stirred for 0.5 hour at 0°C.
The mixture was then added dropwise to a stirred solution of tin (II) chloride (6.8g) in c.HCl (12.4m1) at 0°C over 15 minutes. The mixture was brought to room temperature over 1 hour, then evaporated in vacuo. The residue was taken up in water (30m1), brought to pH 2.5 using lON aqu. NaOH
and the precipitated salts filtered off. 4-Di-methylaminobutanal diethylacetal (Croatica Chemica Acta 36, 103 (1964), l.lg) followed by 'Amberlyst 15' ion exchange resin (Aldrich, 3.Og) was added to the filtrate and the mixture heated for 3 hours at 100°C, filtered and the filtrate evaporated in vacuo.
The residue was treated with hot ethanol, filtered and the filtrate evaporated in vacuo. The residue was triturated with ethyl acetate, filtered and the filtrate evaporated in vacuo. The residue was recrystallised from ethanol to give the desired product as a pale yellow solid (0.75g), mp 280-281°C.
1H NMR and MS were consistent with the proposed structure.
Synthetic Example 22 Preparation of (S)-N,N-dimethyl-2-f5-(2-oxo-1 3-oxazoli-din-4-ylmethyl)-1H-indol-3-yllethylamine (a) (S)-5-(4-Nitrobenzyl-1,3-imidazolidin-2 4-dione Benzyl isocyante (Aldrich, 3.2g) was added to a solution of L-4-nitrophenylalanine (Aldrich, 4.2g) and potassium hydroxide (1.3g) in water (40m1) at 0°C. The mixture was heated at 60-70°C for 2 hours, filtered and the filtrate acidified with c.HCl to give an off-white solid which was filtered off, suspended in 2N aqu. HCl (20m1) and refluxed for 2 hours. The cooled mixture was diluted with water and filtered to give the desired product as a white solid (5.6g) .
(b) (S)-N,N-Dimethyl-2-f5-(2-oxo-1 3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine By steps identical to steps (d) to (f) of Synthetic Example 1 and Synthetic Example 2 or steps (d) and (e) of Synthetic Example 1 and Synthetic Example 3 and steps (e) to (h) of Reference Example 4, the product from step (a) was converted to (S)-N,N-di-methyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine.
Synthetic Example 23 Preparation of (S)-N,N-dimethyl-2-f5-(2-oxo-1 3-oxazo-lidin-4-ylmethyl)-1H-indol-3-yllethylamine (a) (S)-4-(4-Hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride By steps analogous to steps (a) to (c) of Synthetic Example 6, L-4-nitrophenylalanine was converted to (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride.
(b) (S) -4- (4- f2- (3-cvanopropvlidene) hvdrazinol benzvl 1,3-oxazolidin-2-one 1M aqu. HCl (4.Om1) was added to a solution of the product from step (a) (2.4g) in water (35m1) . 3-Cyanopropanol diethylacetal (Aldrich, 1.7g) was added at room temperature and the mixture stirred for 2 hours. Further acetal (0.20g) was added and the mixture stirred for another 20 minutes. The aqueous phase was decanted from the resulting gum and extracted with ethyl acetate. The extracts were combined with the gum and evaporated in vacuo to give the desired product (2.5g).
(c) (S)-3-Cyanomethyl-5-(2-oxo-1,3-oxazolidin-4-yl-methyl)-1H-indol A solution of the product from step (b) (2.5g) and polyphosphate ester (20.Og) in chloroform (40m1) was refluxed for 20 minutes. Ice was added to the cooled mixture and the chloroform evaporated in vacuo. The remaining aqueous phase was extracted with ethyl acetate and the combined extracts evaporated in vacuo to give the desired product as a pale yellow oil (1.8g).
(d) (S)-N,N-Dimethvl-2-f5-(2-oxo-1 3-oxazolidin-4-yl-methyl)-1H-indol-3-yllethylamine A suspension of the product from step (c) (1.3g) and 10% w/w Pd/C (l.Og) in 30% w/w ethanolic dimethyl-amine (25m1) was hydrogenated for 24 hours and filtered through Hyflo. Fresh Pd/C (0.7g) and ethanolic dimethylamine (5ml) were added to the filtrate and hydrogenation continued for a further 16 hours. The mixture was filtered through a silica column using DCM/EtOH/NH40H (40:8:1) as eluant to give the desired product as a colourless foam (0.3g). Elemental analysis and 1H NMR were con-sistent with the proposed structure.
Reference Examples 24 to 31 By methods analogous to those described in Synthetic and Reference Examples 1 to 23, the following compounds were prepared. The NMR and microanalysis for each compound were consistent with the proposed structure.
24) 2-[5-(3-Methyl-2-oxoimidazolidin=4-ylmethyl)-1H-indol-3-yl]-ethylamine maleate 0.75 hydrate, mp 94-98°C;
25) 2-[5-(3-Methyl-2-oxoimidazolidin-4-ylmethyl)-1H-indol-3-yl]-N,N-dimethylethylamine maleate 0.95 hydrate (white lyopholate);
26) 2-(5-[2-(2,5-Dioxoimidazolidinyl)ethyl]-1H-indol-3-yl)ethylamine hydrochloride hydrate, mp 83-85°C;
27) 2-(5-[2-(2,5-Diozoimidazolidinyl)ethyl]-1H-indol-3-yl)-N,N-dimethylethylamine maleate hydrate (pale yellow lyopholate);
28) 5-[2-(2,5-Dioxoimidazolidinyl)ethyl]-3-(1-methyl-4-piperidinyl)-1H-indole hydrochloride, mp 320-322°C
(dec) ;
29) 2-[5-(5-Methyl-2-oxoimidazolidin-4-ylethyl)-1H-indol-3-yl]ethylamine maleate hydrate, mp 99°C
(softens 88°C) ;
30) 5-[3-(4-Piperidyl)-1H-indol-5-ylmethyl]-2,4-imidazolidinedione acetate 1.4 hydrate, mp 92-93°C;
(sofens 86°C) and 31) 2-[5-(1-Methyl-2-oxo-4-imidazolidinylmethyl)-1H-indol-3-yl]ethylamine diacetate 2.75 hydrate (pale yellow lyopholate).
PHARMACEUTICAL FORMULATION EXAMPLES
In the following Examples, the "active ingredient" may be any compound of formula (I) and/or a physiologically acceptable salt, solvate or physiologically functional derivative thereof.
(1) Tablet formulations ( i ) Oral Mg/tablet A B C
Active ingredient 25 25 25 Avicel (Trade-mark) 13 - 7 Lactose 78 47 -Starch (maize) - 9 -Starch (pregelatinised, NF15) - - 32 Sodium starch glycollate 5 - -Povidone 3 3 -Magnesium stearate 1 1 1 (ii) Sublingual Ma/tablet D E
Active ingredient 25 25 Avicel 10 -Lactose - 36 Mannitol 51 57 Sucrose 3 Acacia - 3 Povidone 3 -Magnesium stearate 1 1 Formulations A to E may be prepared by wet granulation of the first six ingredients with the povidone, followed by addition of the magnesium stearate and compression.
(iii) Buccal Ma/tablet Active ingredient 25 Hydroxypropylmethyl cellulose (HPMC) 25 Polycarbophil 39 Magnesium stearate 1 The formulation may be prepared by direct compression of the admixed ingredients.
(2) Capsule formulations ( i ) Powder Ma/capsule F G
Active ingredient 25 25 Avicel (Trade-mark for a micro-crystalline cellulose) 45 -Lactose 153 -Starch (1500 NF) - 117 Sodium starch glycollate -Magnesium stearate 2 2 Formulations F and G may be prepared by admixing the ingredients and filling two-part hard gelatin capsules with the resulting mixture.
(ii) Liquid fill Mg/capsule H I
Active ingredient 25 25 Macrogol 4000 BP (Trade designation for a polyethylene glycol) 200 -Lecithin - 100 Arachis oil - 100 Formulation H may be prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling two-part hard gelatin capsules therewith.
Formulation I may be prepared by dispersing the active ingredient in the lecithin and arachis oil and filling soft, elastic gelatin capsules with the dispersion.
(iii) Controlled release M~psule Active ingredient 25 Avicel (Trade-mark for a micro-crystalline cellulose) 123 Lactose 62 Triethylcitrate 3 Ethyl cellulose 12 The formulation may be prepared by mixing and extruding the first four ingredients and spheronising and drying the extrudate. The dried pellets are coated with ethyl cellulose as a release controlling membrane and filled into two-part, hard gelatin capsules.
(3) Intravenous injection formulation by weight Active ingredient 2%
Hydrochloric acid ) q.s. to pH 7 Citrate buffer ) Water for Injections to 100%
The active ingredient is taken up on the citrate buffer and sufficient hydrochloric acid added to affect solution and adjust the pH to -. The resulting solution is made up to volume and filtered through a micropore filter into sterile glass vials which are sealed and oversealed.
(4) Intranasal formulation by weight Active ingredient 0.5%
Hydrochloric acid ) q.s. to pH 7 Citrate buffer ) Methyl hydroxybenzoate 0.2%
Propyl hydroxybenzoate 0.02%
Water for Injections to 100%
The active ingredient is taken up in a mixture of the hydroxybenzoates and citrate buffer and sufficient hydrochloric acid added to affect solution and adjust the pH to 7. The resulting solution is made up to volume and filtered through a micropore filter into sterile glass vials which are sealed and oversealed.
(5) Intramuscular injection formulation Active ingredient 0.05 g Benzyl alcohol 0.10 g Glycofurol 75 (Trade-mark) 1.45 g Water for Injections q.s. to 3.00 ml The active ingredient is dissolved in the glycofurol.
The benzyl alcohol is added and dissolved and water added to 3 ml. The mixture is filtered through a micropore filter into sterile glass vials which are sealed and oversealed.
(6) Syrup formulation Active ingredient 0.05 g Sorbitol solution 1.50 g Glycerol 1.00 g Sodium benzoate 0.005 g Flavour 0.0125 ml The sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added. The active ingredient is added and dissolved. The resulting solution is mixed with the glycerol and made up to the required volume with purified water.
(7) Suppository formulation Ma/suppositorv Active ingredient (63~,m) * 50 Hard Fat, BP (Witepsol H15-(Trade-mark of Dynamit Nobel 1950 * The active ingredient is used as a powder wherein at least 90% of the particles are of 63~m diameter or less.
One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200~,m sieve and mixed with the molten base using a Silverson mixer fitted with a cutting head until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension which is stirred to ensure a homogenous mix. The entire suspension is then passed through a 250~m stainless steel screen and, with continuous stirring, allowed to cool to 40°C. At a temperature of 38-40°C, 2.Og aliquots of the mixture are filled into suitable plastic moulds and the suppositories allowed to cool to room temperature.
One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200~,m sieve and mixed with the molten base using a Silverson mixer fitted with a cutting head until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension which is stirred to ensure a homogenous mix. The entire suspension is then passed through a 250~m stainless steel screen and, with continuous stirring, allowed to cool to 40°C. At a temperature of 38-40°C, 2.Og aliquots of the mixture are filled into suitable plastic moulds and the suppositories allowed to cool to room temperature.
(8) Pessary formulation Mg/pessary Active ingredient (63~m) 50 Anhydrous dextrose 470 Potato starch 473 Magnesium stearate 473 . 1000 The above ingredients are mixed directly and pessaries prepared by compression of the resulting mixture.
BIOLOGICAL ASSAY
The compounds of formula (I) prepared in the Synthetic Examples were each tested for their activity as agonists for the "5-HT1-like" receptor mediating smooth muscle contraction by the following method.
Right and left lateral saphenous veins were obtained from male New Zealand White rabbits (2.4-2.7 kg) which had been killed by intravenous injection of pentobarbitone sodium (60 mg/kg). Ring segments (3-5 mm wide) prepared from each vessel were suspended between two wire hooks and immersed in 20 ml organ baths containing Krebs' solution (pH 7.4) of the following composition (mM): NaCl 118.41, NaHC03 25.00, KCl 4.75, KHzP04 1.19, MgS04 1.19, glucose 11.10 and CaClz 2.50. Cocaine (30~.M) was present in the Krebs' solution throughout the experiment to prevent the uptake of amines by sympathetic neurones.
The Krebs' solution was maintained at 37°C and continually gassed with 95% oxygen/5% carbon dioxide. Increases in tissue isometric force were measured using Grass FT03C
force displacement transducers and recorded on a Gould BD-212 pen recorder.
A force of l.Og was applied to each preparation and re-established twice during a subsequent period of 30 minutes. During this period, tissues were exposed to pargyline (500~M) to irreversibly inhibit monamine oxidase and to phenoxybenzamine (0.1~M) to inactivate a,l-adrenoceptors. At the end of the 30 minutes, the inhibitors were removed by several changes of the organ bath Krebs' solution.
Agonist activity was assessed by cumulative additions of the test compound, its concentration being increased in 0.5 loglo unit increments until further additions caused no further change in tissue force. In each experiment, the activity of the test compound was compared to the activity of 5-HT. Activity was expressed in terms of the p [Aso] (-loglo [M] , where M is the molar concentration of agonist required to produce half the maximum effect).
The results obtained for the compounds of Synthetic Examples 2/3 and References 4/5 are shown in Table 1.
Table 1 Example Activity ~s o1 2/3 7.0 4/5 6.3 _77_ TOXICITY DATA
The hydrochloride salt of the compound of Synthetic Examples 2/3 was administered orally by gavage to Wistar rats as a solution in distilled water at dosages at 25, 100 and 200mg/kg base and to Beagle dogs at dosages of 0.25, 0.50, 1.0 and 2.Omg/kg base once a day for 14 days.
In a separate dog study over 30 days, the dosage of the free base was increased from 2 mg/kg on Day 1 to 100mg/kg on Day 30. The free base was also administered orally to cynomolgus monkeys at a dosage of 50mg/kg once a day for 15 days.
No evidence of toxicity was observed in any of the aforementioned studies at any of the dosages used.
BIOLOGICAL ASSAY
The compounds of formula (I) prepared in the Synthetic Examples were each tested for their activity as agonists for the "5-HT1-like" receptor mediating smooth muscle contraction by the following method.
Right and left lateral saphenous veins were obtained from male New Zealand White rabbits (2.4-2.7 kg) which had been killed by intravenous injection of pentobarbitone sodium (60 mg/kg). Ring segments (3-5 mm wide) prepared from each vessel were suspended between two wire hooks and immersed in 20 ml organ baths containing Krebs' solution (pH 7.4) of the following composition (mM): NaCl 118.41, NaHC03 25.00, KCl 4.75, KHzP04 1.19, MgS04 1.19, glucose 11.10 and CaClz 2.50. Cocaine (30~.M) was present in the Krebs' solution throughout the experiment to prevent the uptake of amines by sympathetic neurones.
The Krebs' solution was maintained at 37°C and continually gassed with 95% oxygen/5% carbon dioxide. Increases in tissue isometric force were measured using Grass FT03C
force displacement transducers and recorded on a Gould BD-212 pen recorder.
A force of l.Og was applied to each preparation and re-established twice during a subsequent period of 30 minutes. During this period, tissues were exposed to pargyline (500~M) to irreversibly inhibit monamine oxidase and to phenoxybenzamine (0.1~M) to inactivate a,l-adrenoceptors. At the end of the 30 minutes, the inhibitors were removed by several changes of the organ bath Krebs' solution.
Agonist activity was assessed by cumulative additions of the test compound, its concentration being increased in 0.5 loglo unit increments until further additions caused no further change in tissue force. In each experiment, the activity of the test compound was compared to the activity of 5-HT. Activity was expressed in terms of the p [Aso] (-loglo [M] , where M is the molar concentration of agonist required to produce half the maximum effect).
The results obtained for the compounds of Synthetic Examples 2/3 and References 4/5 are shown in Table 1.
Table 1 Example Activity ~s o1 2/3 7.0 4/5 6.3 _77_ TOXICITY DATA
The hydrochloride salt of the compound of Synthetic Examples 2/3 was administered orally by gavage to Wistar rats as a solution in distilled water at dosages at 25, 100 and 200mg/kg base and to Beagle dogs at dosages of 0.25, 0.50, 1.0 and 2.Omg/kg base once a day for 14 days.
In a separate dog study over 30 days, the dosage of the free base was increased from 2 mg/kg on Day 1 to 100mg/kg on Day 30. The free base was also administered orally to cynomolgus monkeys at a dosage of 50mg/kg once a day for 15 days.
No evidence of toxicity was observed in any of the aforementioned studies at any of the dosages used.
Claims (32)
1. A compound of formula (I) wherein n is 1;
W is a group of formula:
wherein R is hydrogen; X is -O-; Y is oxygen and the chiral centre * in W is in its (S) or (R) form or is a mixture thereof in any proportions; and Z is a group of formula:
wherein R1 and R2 are each methyl, or a physiologically acceptable salt or solvate thereof.
W is a group of formula:
wherein R is hydrogen; X is -O-; Y is oxygen and the chiral centre * in W is in its (S) or (R) form or is a mixture thereof in any proportions; and Z is a group of formula:
wherein R1 and R2 are each methyl, or a physiologically acceptable salt or solvate thereof.
2. A compound of formula (I), as defined in claim 1, which compound is N,N-dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine, in its (R) form, or a physiologically acceptable salt or solvate thereof.
3. (S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine or a physiologically acceptable salt or solvate thereof.
4. (S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine.
5. A physiologically acceptable salt of said ethylamine of claim 4.
6. A physiologically acceptable solvate of said ethylamine of claim 4.
7. A compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof, for use in a therapeutic agent.
8. A compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof, for use in the prophylaxis or treatment of a clinical condition for which a 5-hydroxytryptamine-like receptor agonist is indicated.
9. A compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof, for use in the prophylaxis or treatment of migraine.
10. Use of a compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof, in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which a 5-hydroxytryptamine-like receptor agonist is indicated.
11. Use of a compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof, in the manufacture of a medicament for the prophylaxis or treatment of migraine.
12. Use of a compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof as a 5-hydroxytryptamine-like agonist.
13. Use of a compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof as an anti-migraine agent.
14. A compound, salt or solvate of claim 3, 4, 5 or 6, for use as a therapeutic agent.
15. A compound, salt or solvate of claim 3, 4, 5 or 6, for use in the prophylaxis or treatment of a clinical condition for which a 5-hydroxytryptamine receptor agonist is indicated.
16. A compound, salt or solvate of claim 3, 4, 5 or 6, for use in the prophylaxis or treatment of migraine.
17. Use of a compound, salt or solvate of claim 3, 4, 5 or 6, in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which a 5-hydroxytryptamine-like receptor agonist is indicated.
18. Use of a compound, salt or solvate of claim 3, 4, 5 or 6, in the manufacture of a medicament for the prophylaxis or treatment of migraine.
19. Use of a compound, salt or solvate of claim 3, 4, 5 or 6, as a 5-hydroxytryptamine-like agonist.
20. Use of a compound, salt or solvate of claim 3, 4, 5 or 6, as an anti-migraine agent.
21. A pharmaceutical composition comprising a compound of formula (I), as claimed in claim 1 or 2, or a physiologically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising a physiologically effective, acceptable amount of a compound, salt or solvate of claim 3, 4, 5 or 6, in association with a pharmaceutically acceptable carrier.
23. A 5-hydroxytryptamine-like agonist pharmaceutical composition comprising an acceptable, 5-hydroxytryptamine-like agonistic amount of a compound of formula (I), as defined in claim 1 or 2, or a physiologically acceptable salt or solvate thereof, in association with a pharmaceutically acceptable carrier.
24. An anti-migraine pharmaceutical composition comprising an acceptable anti-migraine effective amount of a compound of formula (I), as defined in claim 1 or 2, or a physiologically acceptable salt or solvate thereof, in association with a pharmaceutically acceptable carrier.
25. A 5-hydroxytryptamine-like agonist pharmaceutical composition comprising an acceptable 5-hydroxytryptamine-like agonistic amount of a compound, salt or solvate of claim 3, 4, 5 or 6, in association with a pharmaceutically acceptable carrier.
26. An anti-migraine pharmaceutical composition comprising an acceptable anti-migraine effective amount of a compound, salt or solvate of claim 3, 4, 5 or 6, in association with a pharmaceutically acceptable carrier.
27. A pharmaceutical composition as claimed in claim 21, which is in the form of a tablet or capsule.
28. A composition as claimed in claim 22, 23 or 24, in the form of a tablet or capsule.
29. A composition as claimed in claim 25 or 26, in the form of a tablet or capsule.
30. A process for the preparation of a compound of formula (I) wherein n is 1;
W is a group of formula:
wherein R is hydrogen; X is -O-; Y is oxygen and the chiral centre * in W is in its (S) or (R) form or is a mixture thereof in any proportions; and Z is a group of formula:
wherein R1 and R2 are each methyl or a physiologically acceptable salt or solvate thereof, which comprises:
(a) reacting a compound of formula (II) wherein n and W are as hereinbefore defined, with a compound of formula (III) or a carbonyl-protected form thereof, wherein L is a leaving group or protected amino group which may be converted in situ to an amine group or is -NR1R2 wherein R1 and R2 are as hereinbefore defined, and where L is a leaving group or a protected amino group, converting L to a group of formula -NR1R2, wherein R1 and R2 are as defined above; or (b) reacting a compound of formula (XV) wherein n, R, Z and X are as hereinbefore defined, with a compound of formula (VII) wherein Y is as hereinbefore defined and L and L', which may be the same or different are leaving groups, and when desired, converting the compound of formula (I) so formed to a corresponding physiologically acceptable salt or solvate thereof.
W is a group of formula:
wherein R is hydrogen; X is -O-; Y is oxygen and the chiral centre * in W is in its (S) or (R) form or is a mixture thereof in any proportions; and Z is a group of formula:
wherein R1 and R2 are each methyl or a physiologically acceptable salt or solvate thereof, which comprises:
(a) reacting a compound of formula (II) wherein n and W are as hereinbefore defined, with a compound of formula (III) or a carbonyl-protected form thereof, wherein L is a leaving group or protected amino group which may be converted in situ to an amine group or is -NR1R2 wherein R1 and R2 are as hereinbefore defined, and where L is a leaving group or a protected amino group, converting L to a group of formula -NR1R2, wherein R1 and R2 are as defined above; or (b) reacting a compound of formula (XV) wherein n, R, Z and X are as hereinbefore defined, with a compound of formula (VII) wherein Y is as hereinbefore defined and L and L', which may be the same or different are leaving groups, and when desired, converting the compound of formula (I) so formed to a corresponding physiologically acceptable salt or solvate thereof.
31. A method of preparing a medicament which comprises:
(a) preparing a compound of formula (I) , as defined in claim 1, or a physiologically acceptable salt or solvate thereof by a process as claimed in claim 30, and (b) admixing the product from step (a) with a pharmaceutically acceptable carrier.
(a) preparing a compound of formula (I) , as defined in claim 1, or a physiologically acceptable salt or solvate thereof by a process as claimed in claim 30, and (b) admixing the product from step (a) with a pharmaceutically acceptable carrier.
32. A method as claimed in claim 31, which comprises an additional step (c) wherein the admixture from step (b) is formed into a tablet or capsule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002282890A CA2282890C (en) | 1990-06-07 | 1991-06-06 | Therapeutic heterocyclic compounds |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9012672.3 | 1990-06-07 | ||
GB909012672A GB9012672D0 (en) | 1990-06-07 | 1990-06-07 | Therapeutic heterocyclic compounds |
GB9102182.4 | 1991-02-01 | ||
GB919102182A GB9102182D0 (en) | 1991-02-01 | 1991-02-01 | Therapeutic heterocyclic compounds |
PCT/GB1991/000908 WO1991018897A1 (en) | 1990-06-07 | 1991-06-06 | Therapeutic heterocyclic compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002282890A Division CA2282890C (en) | 1990-06-07 | 1991-06-06 | Therapeutic heterocyclic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2064815A1 CA2064815A1 (en) | 1991-12-08 |
CA2064815C true CA2064815C (en) | 1999-11-16 |
Family
ID=26297174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002282890A Expired - Lifetime CA2282890C (en) | 1990-06-07 | 1991-06-06 | Therapeutic heterocyclic compounds |
CA002064815A Expired - Lifetime CA2064815C (en) | 1990-06-07 | 1991-06-06 | Therapeutic heterocyclic compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002282890A Expired - Lifetime CA2282890C (en) | 1990-06-07 | 1991-06-06 | Therapeutic heterocyclic compounds |
Country Status (37)
Country | Link |
---|---|
US (3) | US5399574A (en) |
EP (2) | EP0636623B1 (en) |
JP (1) | JP2738461B2 (en) |
KR (1) | KR100215627B1 (en) |
AT (2) | ATE204275T1 (en) |
AU (1) | AU646871B2 (en) |
CA (2) | CA2282890C (en) |
CZ (1) | CZ288351B6 (en) |
DE (3) | DE69132691T2 (en) |
DK (1) | DK0486666T3 (en) |
EG (1) | EG19650A (en) |
ES (1) | ES2104708T3 (en) |
FI (3) | FI105686B (en) |
GR (1) | GR3024828T3 (en) |
HK (1) | HK1000534A1 (en) |
HR (1) | HRP940524B1 (en) |
HU (2) | HU219974B (en) |
IE (1) | IE911931A1 (en) |
IL (3) | IL114690A (en) |
LT (1) | LT3264B (en) |
LU (1) | LU90205I2 (en) |
LV (1) | LV10274B (en) |
MC (1) | MC2210A1 (en) |
MX (1) | MX9203421A (en) |
MY (1) | MY110226A (en) |
NL (1) | NL980001I2 (en) |
NO (2) | NO300634B1 (en) |
NZ (1) | NZ238424A (en) |
PL (1) | PL166214B1 (en) |
PT (1) | PT97888B (en) |
RU (1) | RU2160736C2 (en) |
SA (1) | SA05260104B1 (en) |
SI (2) | SI21560B (en) |
SK (1) | SK281621B6 (en) |
UA (1) | UA37178C2 (en) |
WO (1) | WO1991018897A1 (en) |
YU (1) | YU48855B (en) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ283018B6 (en) * | 1991-02-01 | 1997-12-17 | Merck Sharp And Dohme Limited | Imidazole, triazole and tetrazole derivatives, process of their preparation, their use and pharmaceuticals based thereon |
TW263508B (en) * | 1991-02-12 | 1995-11-21 | Pfizer | |
US5639752A (en) * | 1991-11-25 | 1997-06-17 | Pfizer Inc | Indole derivatives |
GB9201038D0 (en) * | 1992-01-16 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
TW288010B (en) * | 1992-03-05 | 1996-10-11 | Pfizer | |
DE69330713T2 (en) * | 1992-03-13 | 2002-07-04 | Merck Sharp & Dohme | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES |
GB9207396D0 (en) * | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
US6380233B1 (en) | 1992-04-07 | 2002-04-30 | Pfizer Inc | Indole derivatives as 5-HT1 agonists |
US5747501A (en) | 1992-04-07 | 1998-05-05 | Pfizer, Inc. | Indole derivatives |
WO1993021180A1 (en) * | 1992-04-10 | 1993-10-28 | Pfizer Inc. | Acylaminoindole derivatives as 5-ht1 agonists |
GB9207930D0 (en) * | 1992-04-10 | 1992-05-27 | Pfizer Ltd | Indoles |
GB9208161D0 (en) * | 1992-04-14 | 1992-05-27 | Pfizer Ltd | Indoles |
GB9208463D0 (en) * | 1992-04-16 | 1992-06-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9209882D0 (en) * | 1992-05-07 | 1992-06-24 | Glaxo Lab Sa | Compositions |
GB9211277D0 (en) | 1992-05-28 | 1992-07-15 | Glaxo Group Inc | Pharmaceutical compositions |
AU672802B2 (en) * | 1992-07-24 | 1996-10-17 | Merck Sharp & Dohme Limited | Imidazole, triazole and tetrazole derivatives |
GB9216009D0 (en) * | 1992-07-28 | 1992-09-09 | Almirall Lab | New indol derivatives |
IL106445A (en) * | 1992-07-30 | 1998-01-04 | Merck Sharp & Dohme | 4-substituted 1, 2, 4-triazole derivatives, their preparation and pharmaceutical compositions containing them |
ES2056025B1 (en) * | 1992-10-08 | 1995-05-01 | Almirall Lab | NEW DERIVATIVES OF INDOL. |
TW251284B (en) * | 1992-11-02 | 1995-07-11 | Pfizer | |
GB9226532D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
FR2701026B1 (en) * | 1993-02-02 | 1995-03-31 | Adir | New derivatives of indole, indazole and benzisoxazole, process for their preparation and pharmaceutical compositions containing them. |
ES2070087B1 (en) * | 1993-08-13 | 1996-02-16 | Pfizer | DERIVATIVES OF INDOL |
BR9407402A (en) * | 1993-08-31 | 1996-11-05 | Pfizer | Derivatives of 5-arylindole |
US6423731B2 (en) | 1994-01-06 | 2002-07-23 | Zeneca Limited | Indole derivatives as prodrugs of 5-HT1-like receptor agonists |
US5468768A (en) * | 1994-01-06 | 1995-11-21 | Bristol-Myers Squibb Company | Antimigraine derivatives of indolylcycloalkanylamines |
GB9401436D0 (en) * | 1994-01-26 | 1994-03-23 | Wellcome Found | Therapeutic heterocyclic compounds |
CA2190501A1 (en) * | 1994-05-19 | 1995-11-30 | Jose Luis Castro Pineiro | Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists |
ES2161892T3 (en) * | 1994-06-01 | 2001-12-16 | Astrazeneca Ab | DERIVATIVES OF INDOL AS PROPHARMACES OF AGONISTS OF THE RECEIVERS RELATED TO 5-HT1. |
JP3155008B2 (en) * | 1994-07-26 | 2001-04-09 | ファイザー・インコーポレーテッド | 4-indole derivatives as serotonin agonists and antagonists |
US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
GB9423682D0 (en) * | 1994-11-23 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
WO1996017842A1 (en) * | 1994-12-06 | 1996-06-13 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
DE4443892A1 (en) * | 1994-12-09 | 1996-06-13 | Bayer Ag | 4- (Quinolin-2-yl-methoxy) phenyl acetic acid derivatives |
GB9501865D0 (en) * | 1995-01-31 | 1995-03-22 | Merck Sharp & Dohme | Therapeutic agents |
CA2215322A1 (en) * | 1995-03-20 | 1996-09-26 | Stephen Warren Kaldor | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists |
GB9515060D0 (en) * | 1995-07-22 | 1995-09-20 | Wellcome Found | Therapeutic heterocyclic compounds |
GB9515305D0 (en) * | 1995-07-26 | 1995-09-20 | Wellcome Found | Therapeutic heterocyclic compounds |
US6909005B1 (en) * | 1995-08-07 | 2005-06-21 | Astrazeneca Uk Limited | One post synthesis of 2-oxazolidinone derivatives |
GB9516143D0 (en) | 1995-08-07 | 1995-10-04 | Wellcome Found | Improved chemical synthesis |
GB9516145D0 (en) * | 1995-08-07 | 1995-10-04 | Wellcome Found | Improved chemical synthesis |
JPH11513666A (en) * | 1995-10-10 | 1999-11-24 | イーライ・リリー・アンド・カンパニー | N- [2-substituted-3- (2-aminoethyl) -1H-indol-5-yl] -amide: a novel 5-HT (lower 1F) agonist |
WO1997016446A1 (en) * | 1995-11-02 | 1997-05-09 | Merck Sharp & Dohme Limited | Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors |
GB9609374D0 (en) * | 1996-05-03 | 1996-07-10 | Merck Sharp & Dohme | Therapeutic agents |
US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
GB9706089D0 (en) | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
AR017200A1 (en) | 1997-12-23 | 2001-08-22 | Astrazeneca Ab | INHIBITING COMPOUNDS OF PROTEIN CINASE C, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, PHARMACEUTICAL FORMULATIONS THAT UNDERSTAND THEM, USE THE SAME AND PROCESS FOR THE SYNTHESIS OF SUCH COMPOUNDS |
SE9800835D0 (en) | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
AU4961499A (en) * | 1998-06-26 | 2000-01-17 | Eli Lilly And Company | 5-HT1f agonists |
US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
US6346625B1 (en) * | 1999-06-23 | 2002-02-12 | Astrazeneca Ab | Protein kinase inhibitors |
GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
CA2427098A1 (en) * | 2000-11-29 | 2002-06-06 | John Mehnert Schaus | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence |
US20070122353A1 (en) * | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7458374B2 (en) * | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20030051728A1 (en) * | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US8329734B2 (en) | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
US20030013753A1 (en) * | 2001-06-05 | 2003-01-16 | Ronald Aung-Din | Transdermal migraine therapy |
US20030017175A1 (en) * | 2001-07-05 | 2003-01-23 | R.T. Alamo Ventures I, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
US6685951B2 (en) | 2001-07-05 | 2004-02-03 | R. T. Alamo Ventures I, Inc. | Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine |
US20030198669A1 (en) * | 2001-07-05 | 2003-10-23 | R.T. Alamo Ventures I, Llc | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
JP4455992B2 (en) | 2002-06-21 | 2010-04-21 | スベン ライフ サイエンシズ リミティド | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, methods for their production, and pharmaceutical compositions containing them |
DK1523486T3 (en) | 2002-06-21 | 2008-03-03 | Suven Life Sciences Ltd | Tetracyclic arylsulfonyl indoles with serotonin receptor affinity |
ES2204302B2 (en) | 2002-08-07 | 2005-03-01 | Laboratorios Vita, S.A. | PROCEDURE FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND. |
US20040105818A1 (en) * | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) * | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
JP4559230B2 (en) | 2002-11-28 | 2010-10-06 | スベン ライフ サイエンシズ リミティド | Novel N-arylsulfonyl-3-substituted indoles having affinity for serotonin receptors, methods for their preparation, and pharmaceutical compositions containing them |
PT1567492E (en) | 2002-11-28 | 2013-07-22 | Suven Life Sciences Ltd | N-arylsulfonyl-3-aminoalkoxyindoles |
BRPI0316895C1 (en) | 2002-12-18 | 2021-05-25 | Suven Life Sciences Ltd | compound, process for preparing the compound, pharmaceutical composition and use of the compound |
CA2508290C (en) | 2002-12-20 | 2017-02-28 | Ciba Specialty Chemicals Holding Inc. | Synthesis of amines and intermediates for the synthesis thereof |
WO2004063175A1 (en) * | 2003-01-13 | 2004-07-29 | Natco Pharma Limited | A novel and an improved process for the preparation of (s)-4-(4-aminobenzyl)-2- oxazolidinone |
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
US20040192958A1 (en) * | 2003-03-25 | 2004-09-30 | Hyatt John Anthony | Process for preparing derivatives of 4-halobutyraldehyde |
WO2004104490A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
AR044688A1 (en) * | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | USEFUL THERAPEUTIC AGENTS FOR THE TREATMENT OF PAIN |
CA2529528A1 (en) * | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
CN101914088A (en) * | 2003-07-24 | 2010-12-15 | 尤罗塞尔蒂克股份有限公司 | Piperidine compounds and pharmaceutical compositions containing them |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
EP1711493A2 (en) * | 2004-02-06 | 2006-10-18 | CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement | Crystalline forms of zolmitriptan |
US7540286B2 (en) * | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US7581540B2 (en) * | 2004-08-12 | 2009-09-01 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
WO2006055964A2 (en) * | 2004-11-19 | 2006-05-26 | Teva Pharmaceutical Industries Ltd. | Zolmitriptan crystal forms |
DK1883451T3 (en) | 2005-04-13 | 2011-03-14 | Neuraxon Inc | Substituted indole compounds with NOS inhibitory effect |
ATE510836T1 (en) | 2006-01-19 | 2011-06-15 | Matrix Lab Ltd | CONVERSION OF AN AROMATIC DIAZONIUM SALT INTO AN ARYLHYDRAZINE |
AR060451A1 (en) * | 2006-04-13 | 2008-06-18 | Neuraxon Inc | INDOL 1.5 AND 3,6-SUBSTITUTED COMPOUNDS WITH INHIBITORY ACTIVITY OF US |
WO2008018090A2 (en) * | 2006-08-09 | 2008-02-14 | Matrix Laboratories Ltd | An improved process for the preparation of zolmitriptan |
JP2010507585A (en) * | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | Substituted indole |
KR20090129998A (en) | 2007-02-11 | 2009-12-17 | 맵 파마슈티컬스, 인코포레이티드 | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
CZ2007158A3 (en) * | 2007-02-26 | 2008-10-22 | Zentiva, A. S. | Process for preparing zolmitriptan |
EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
AU2008246202B2 (en) * | 2007-04-27 | 2011-12-01 | Purdue Pharma L.P. | Therapeutic agents useful for treating pain |
JP5462784B2 (en) | 2007-04-27 | 2014-04-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | TRPV1 antagonists and uses thereof |
EP2201003A1 (en) * | 2007-10-03 | 2010-06-30 | Generics Ýuk¨Limited | Process for the preparation of zolmitriptan, salts and solvates thereof |
NZ586082A (en) * | 2007-11-16 | 2013-03-28 | Neuraxon Inc | Indole compounds and methods for treating visceral pain |
CA2705833A1 (en) * | 2007-11-16 | 2009-05-22 | Subhash C. Annedi | 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
EP2219449A4 (en) * | 2007-11-16 | 2010-10-27 | Univ Arizona State | Methods for treating visceral pain |
CN101181267B (en) * | 2007-11-30 | 2010-09-08 | 重庆医科大学医药研究所 | Zolmitriptan tongue tablet |
KR101517415B1 (en) | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant |
WO2010005507A1 (en) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
US20100217013A1 (en) * | 2008-12-15 | 2010-08-26 | Wenge Li | Enantioselective process for the preparation of zolmitriptan |
WO2010151804A1 (en) * | 2009-06-26 | 2010-12-29 | Map Pharmaceuticals, Inc. | Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
US20110038928A1 (en) * | 2009-08-12 | 2011-02-17 | Glenmark Generics Ltd | Orally disintegrating tablets of zolmitriptan |
KR101825972B1 (en) | 2010-10-15 | 2018-02-06 | 콘테라 파르마 에이피에스 | Combinations of serotonin receptor agonists for treatment of movement disorders |
PT2723732T (en) | 2011-06-22 | 2017-02-17 | Purdue Pharma Lp | Trpv1 antagonists including dihydroxy substituent and uses thereof |
AU2012287120B2 (en) | 2011-07-22 | 2017-02-23 | The University Of Chicago | Treatments for migraine and related disorders |
WO2013057739A2 (en) * | 2011-09-02 | 2013-04-25 | Emcure Pharmaceuticals Limited | An improved process for preparation of zolmitriptan |
PT2838517T (en) | 2012-04-18 | 2018-01-04 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
CA2895816C (en) | 2012-12-21 | 2021-02-23 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
US20160256410A1 (en) | 2015-03-02 | 2016-09-08 | Afgin Pharma, Llc | Topical regional neuro-affective therapy in mammals with cannabinoids |
US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
WO2017122161A1 (en) | 2016-01-15 | 2017-07-20 | Cadila Healthcare Limited | An intranasal composition comprising 5ht1b/1d receptor agonists |
AU2017211684B2 (en) | 2016-01-27 | 2022-10-06 | Instar Technologies A.S. | Oromucosal nanofiber carriers for therapeutic treatment |
US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
EP3766483A1 (en) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
US20210322343A1 (en) | 2020-04-15 | 2021-10-21 | Farzana Shaheen | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB148879A (en) * | 1919-02-14 | 1921-11-10 | Emil Vincance Noser | Locks for shift levers of automobiles |
US3320282A (en) * | 1962-10-29 | 1967-05-16 | Pfizer & Co C | Process for preparing esters of 2-hydroxy-3-(3-indolyl) alkanoic acids |
US3879410A (en) * | 1971-02-08 | 1975-04-22 | Messrs Lab Guidotti & C S P A | 4-Aryl-4-oxazolin-2-ones exhibiting myotonic and myorelaxing activity |
BE795457A (en) * | 1972-02-16 | 1973-08-16 | Clin Midy | INDOLIC AMINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS |
FR2179582B1 (en) * | 1972-04-13 | 1975-10-10 | Synthelabo | |
US3873559A (en) * | 1973-03-30 | 1975-03-25 | Squibb & Sons Inc | Heterocyclic carboxamido thiazolinyl indoles |
US4042595A (en) * | 1973-08-01 | 1977-08-16 | Snam Progetti S.P.A. | Processes for the production of heterocyclic compounds |
IT995110B (en) * | 1973-08-01 | 1975-11-10 | Snam Progetti | PROCEDURE FOR THE PRODUCTION OF HETEROCYCLIC COMPOUNDS AND OBTAINED PRODUCTS |
US3931229A (en) * | 1973-08-23 | 1976-01-06 | Warner-Lambert Company | 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles |
US4049816A (en) * | 1975-03-24 | 1977-09-20 | Beecham Group Limited | Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones |
FR2315925A1 (en) * | 1975-07-04 | 1977-01-28 | Nippon Chemiphar Co | NEW 5-BENZYL-2-OXAZOLIDONE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION |
GB1482879A (en) * | 1975-07-24 | 1977-08-17 | Nippon Chemiphar Co | 5-benzyl-2-oxazolidone derivatives and a process for producing the same |
GB1469200A (en) * | 1975-11-28 | 1977-03-30 | Warner Lambert Co | 3-thiomethyl-2-2-dialkylamino-ethyl-indoles |
DE2557341A1 (en) * | 1975-12-19 | 1977-06-30 | Hoechst Ag | BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
IT1109002B (en) * | 1977-09-22 | 1985-12-16 | Menarini Sas | DERIVATIVES OF 2 OXAZOLIDONE AND THEIR PREPARATION METHODS |
US4198501A (en) * | 1977-12-20 | 1980-04-15 | Hoffmann-La Roche Inc. | Synthesis of tryptophans |
US4137404A (en) * | 1977-12-20 | 1979-01-30 | Hoffmann-La Roche Inc. | Synthesis of tryptophans |
JPS6014032B2 (en) * | 1978-01-20 | 1985-04-11 | 日本ケミフア株式会社東京 | 5-phenethyl-2-oxazolidone derivative and its production method |
US4348393A (en) * | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
DE2933636A1 (en) * | 1978-08-30 | 1980-03-20 | Sandoz Ag | NEW N-PHENYLINDOL DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE COMPOUNDS |
ZA795239B (en) * | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
US4255432A (en) * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4272555A (en) * | 1979-09-21 | 1981-06-09 | Monsanto Company | Conversion of carbon-containing materials to carbon monoxide |
EP0083566A1 (en) * | 1980-04-10 | 1983-07-13 | Sandoz Ag | Isoxazolyl indoles |
JPS574986A (en) * | 1980-06-13 | 1982-01-11 | Paamakemu Asia:Kk | Preparation of oxazolidine derivative |
US4753956A (en) * | 1981-01-02 | 1988-06-28 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4367234A (en) * | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
BE889931A (en) * | 1980-08-12 | 1982-02-11 | Glaxo Group Ltd | INDOLIC DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATIONS AS MEDICAMENTS |
ZW19381A1 (en) * | 1980-08-12 | 1983-03-09 | Glaxo Group Ltd | Heterocyclic compounds |
NL8103769A (en) * | 1980-08-12 | 1982-03-01 | Glaxo Group Ltd | HETEROCYCLIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AS AN ACTIVE COMPONENT. |
US4407811A (en) * | 1981-01-02 | 1983-10-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4399296A (en) * | 1981-01-02 | 1983-08-16 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
US4448971A (en) * | 1981-01-02 | 1984-05-15 | Pfizer Inc. | Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones |
JPS57169458A (en) * | 1981-04-13 | 1982-10-19 | Paamakemu Asia:Kk | Preparation of indole derivative |
CH656124A5 (en) * | 1982-04-13 | 1986-06-13 | Sandoz Ag | 2-SUBSTITUTED-3-INDOLAMINES, METHOD FOR THE PRODUCTION AND USE THEREOF. |
GR79215B (en) * | 1982-06-07 | 1984-10-22 | Glaxo Group Ltd | |
US4803218A (en) * | 1982-09-29 | 1989-02-07 | Mcneilab, Inc. | 3-aminoalkyl-1H-indole-5-urea and amide derivatives |
US4500717A (en) * | 1983-03-28 | 1985-02-19 | The Dow Chemical Company | Process for preparation of 2-oxazolidinones |
US4831153A (en) * | 1983-06-27 | 1989-05-16 | The Dow Chemical Company | Preparation of N-vinyl-2-oxazolidinone |
GB8321813D0 (en) * | 1983-08-12 | 1983-09-14 | Vickers Plc | Radiation sensitive compounds |
DE3333450A1 (en) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | CARBONYL METHYLENE HETEROCYCLES CONTAINING TRIHALOGEN METHYL GROUPS, METHOD FOR THE PRODUCTION THEREOF AND LIGHT-SENSITIVE MIXTURE THAT CONTAINS THESE COMPOUNDS |
HU196752B (en) * | 1983-12-06 | 1989-01-30 | Glaxo Group Ltd | Process for production of medical compositions containing indole-derivatives and these compounds |
DE3430284A1 (en) * | 1984-08-17 | 1986-02-27 | Troponwerke GmbH & Co KG, 5000 Köln | NEW TRYPTAMINE DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND THEIR USE |
SE8505715L (en) * | 1984-12-04 | 1986-06-05 | Glaxo Group Ltd | indole derivatives |
GB8431426D0 (en) * | 1984-12-13 | 1985-01-23 | Glaxo Group Ltd | Chemical compounds |
DE3514696A1 (en) * | 1985-04-24 | 1986-11-06 | Bayer Ag, 5090 Leverkusen | N-INDOLYLETHYL SULPHONIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
DE3531658A1 (en) * | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | HETEROCYCLICALLY SUBSTITUTED INDOLE, INTERMEDIATE PRODUCTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS |
DE3678805D1 (en) * | 1985-11-08 | 1991-05-23 | Glaxo Group Ltd | INDOLDER DERIVATIVES. |
GB8531612D0 (en) * | 1985-12-23 | 1986-02-05 | Beecham Wuelfing Gmbh & Co Kg | Compounds |
SE451840B (en) * | 1986-01-03 | 1987-11-02 | Astra Laekemedel Ab | OPTICALLY PURE MONOHYDRATED OF S - (-) - 1-PROPYL-2 ', 6'-PIPECOLOXYLIDE HYDROCHLORIDE, SET TO PREPARE THIS AND PHARMACEUTICAL PREPARATIONS FOR LOCAL ANCHORING |
GB8600397D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
GB8600398D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
GB8607824D0 (en) * | 1986-03-27 | 1986-04-30 | Glaxo Group Ltd | Chemical compounds |
DE3643957A1 (en) * | 1986-12-22 | 1988-06-30 | Bayer Ag | SUBSTITUTED N-METHYLISOXAZOLIDINE |
GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
ATE92057T1 (en) * | 1987-08-13 | 1993-08-15 | Glaxo Group Ltd | INDOLE DERIVATIVES. |
DE3730777A1 (en) * | 1987-09-12 | 1989-03-23 | Basf Ag | METHOD FOR PRODUCING IMIDAZOLIDINONES AND OXAZOLIDINONES |
US4921869A (en) * | 1987-10-09 | 1990-05-01 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents |
US4965268A (en) * | 1987-10-09 | 1990-10-23 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents |
US4801600A (en) * | 1987-10-09 | 1989-01-31 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents |
GB8724912D0 (en) * | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
DE3823299A1 (en) * | 1988-07-07 | 1990-01-11 | Schering Ag | SUBSTITUTED PHENYL-PYRROLIDIN-2-ONE, -OXAZOLIDIN-2-ONE AND -IMIDAZOLIDIN-2-ONE, THEIR PRODUCTION AND USE IN MEDICINAL PRODUCTS |
GB8819024D0 (en) * | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
US5164510A (en) * | 1988-09-15 | 1992-11-17 | The Upjohn Company | 5'Indolinyl-5β-amidomethyloxazolidin-2-ones |
DE68929303T2 (en) * | 1988-09-15 | 2002-05-02 | Upjohn Co | 3- (nitrogen substituted) phenyl-5-beta-amidomethyloxazoliden-2-one |
DE3939238A1 (en) * | 1989-11-28 | 1991-05-29 | Bayer Ag | HETEROCYCLICALLY SUBSTITUTED ACRYLIC ACID ESTERS |
DE4013907A1 (en) * | 1990-04-26 | 1991-10-31 | Schering Ag | Prepn. of 3-alkylamino methyl-indole derivs. from indole deriv. |
CZ283018B6 (en) * | 1991-02-01 | 1997-12-17 | Merck Sharp And Dohme Limited | Imidazole, triazole and tetrazole derivatives, process of their preparation, their use and pharmaceuticals based thereon |
GB9104136D0 (en) * | 1991-02-27 | 1991-04-17 | Merck Sharp & Dohme | Therapeutic agents |
US5409941A (en) * | 1992-02-03 | 1995-04-25 | Pfizer Inc. | 5-heteroyl indole derivatives |
-
1991
- 1991-06-06 SK SK1727-91A patent/SK281621B6/en not_active IP Right Cessation
- 1991-06-06 PL PL91293486A patent/PL166214B1/en unknown
- 1991-06-06 SI SI9119001A patent/SI21560B/en active Search and Examination
- 1991-06-06 AT AT94115107T patent/ATE204275T1/en active
- 1991-06-06 AU AU79570/91A patent/AU646871B2/en not_active Expired
- 1991-06-06 IL IL11469091A patent/IL114690A/en not_active IP Right Cessation
- 1991-06-06 CA CA002282890A patent/CA2282890C/en not_active Expired - Lifetime
- 1991-06-06 DE DE69132691T patent/DE69132691T2/en not_active Expired - Lifetime
- 1991-06-06 MY MYPI91001002A patent/MY110226A/en unknown
- 1991-06-06 JP JP3510103A patent/JP2738461B2/en not_active Expired - Lifetime
- 1991-06-06 DE DE1991627260 patent/DE19775091I2/en active Active
- 1991-06-06 ES ES91911486T patent/ES2104708T3/en not_active Expired - Lifetime
- 1991-06-06 PT PT97888A patent/PT97888B/en not_active IP Right Cessation
- 1991-06-06 SI SI9111010A patent/SI9111010B/en active Search and Examination
- 1991-06-06 RU RU95112537/04A patent/RU2160736C2/en active
- 1991-06-06 DE DE69127260T patent/DE69127260T2/en not_active Expired - Lifetime
- 1991-06-06 AT AT91911486T patent/ATE156823T1/en active
- 1991-06-06 EP EP94115107A patent/EP0636623B1/en not_active Expired - Lifetime
- 1991-06-06 DK DK91911486.8T patent/DK0486666T3/en active
- 1991-06-06 CA CA002064815A patent/CA2064815C/en not_active Expired - Lifetime
- 1991-06-06 EP EP91911486A patent/EP0486666B1/en not_active Expired - Lifetime
- 1991-06-06 HU HU9200384A patent/HU219974B/en unknown
- 1991-06-06 IE IE193191A patent/IE911931A1/en not_active IP Right Cessation
- 1991-06-06 IL IL9839291A patent/IL98392A/en not_active IP Right Cessation
- 1991-06-06 EG EG35491A patent/EG19650A/en active
- 1991-06-06 UA UA93002089A patent/UA37178C2/en unknown
- 1991-06-06 WO PCT/GB1991/000908 patent/WO1991018897A1/en active IP Right Grant
- 1991-06-06 KR KR1019920700284A patent/KR100215627B1/en not_active IP Right Cessation
- 1991-06-06 NZ NZ238424A patent/NZ238424A/en not_active IP Right Cessation
- 1991-06-06 CZ CS19911727A patent/CZ288351B6/en not_active IP Right Cessation
- 1991-06-06 MC MC91908D patent/MC2210A1/en unknown
- 1991-06-06 YU YU101091A patent/YU48855B/en unknown
- 1991-06-06 US US07/838,233 patent/US5399574A/en not_active Expired - Lifetime
- 1991-08-05 SA SA05260104A patent/SA05260104B1/en unknown
-
1992
- 1992-02-06 NO NO920494A patent/NO300634B1/en not_active IP Right Cessation
- 1992-02-06 FI FI920503A patent/FI105686B/en not_active IP Right Cessation
- 1992-06-25 MX MX9203421A patent/MX9203421A/en unknown
-
1993
- 1993-03-15 LT LTIP419A patent/LT3264B/en not_active IP Right Cessation
- 1993-06-30 LV LVP-93-872A patent/LV10274B/en unknown
-
1994
- 1994-09-14 HR HRP-1010/91A patent/HRP940524B1/en not_active IP Right Cessation
- 1994-12-05 US US08/341,206 patent/US5466699A/en not_active Expired - Lifetime
-
1995
- 1995-06-06 US US08/471,229 patent/US5863935A/en not_active Expired - Lifetime
- 1995-06-29 HU HU95P/P00532P patent/HU211479A9/en unknown
- 1995-07-21 IL IL11469095A patent/IL114690A0/en unknown
-
1996
- 1996-01-12 FI FI960155A patent/FI106262B/en not_active IP Right Cessation
-
1997
- 1997-09-24 GR GR970402466T patent/GR3024828T3/en unknown
- 1997-11-07 HK HK97102131A patent/HK1000534A1/en not_active IP Right Cessation
-
1998
- 1998-01-06 NL NL980001C patent/NL980001I2/en unknown
- 1998-01-21 NO NO1998005C patent/NO1998005I1/en unknown
- 1998-01-28 LU LU90205C patent/LU90205I2/en unknown
-
2000
- 2000-06-13 FI FI20001406A patent/FI20001406A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2064815C (en) | Therapeutic heterocyclic compounds | |
IE84467B1 (en) | Therapeutic heterocyclic compounds | |
US5744466A (en) | Therapeutic heterocyclic compounds | |
EP0629199B1 (en) | Indole derivatives as 5-ht1 agonists | |
RU2110517C1 (en) | N,n-dimethyl-2-(5-(2-oxo-1,3-oxazolidine-4-yl-methyl)-1h-indo- -le-3-yl)-ethylamine, its physiologically acceptable salt or solvate, method of its synthesis, drug used as an agonist of "5-ht1-like" receptor in mammals, method of drug agent preparing | |
EP0765322A1 (en) | Indole derivatives as prodrugs of 5-ht 1?-like receptor agonists | |
IE83785B1 (en) | Indole derivatives as 5-HT1 like agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |